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In middle and low income countries, childhood cancer is rare when compared to trauma 
and infectious diseases.  There is a paucity of literature regarding the cost and cost-
effectiveness of treatment for paediatric cancers to guide decisions on resource allocation. 
Burkitt Lymphoma (BL) is a fairly common paediatric cancer in South-Africa.  Optimal 
treatment and supportive care of BL translates in high cure rates.  
Study aim 
To determine the cost to avert 1 Disability Adjusted Life Year (DALY) in treating children 
with Burkitt Lymphoma in Tygerberg Children’s Hospital and whether this meets the WHO-
CHOICE threshold of cost-effectiveness. 
Methodology 
The study is a retrospective, longitudinal descriptive audit and cost-effectiveness analysis.  
Data was collected from all available records at Tygerberg Children’s Hospital and total 
direct cost for treatment and follow up was calculated.  Using the WHO’s ‘Choosing 
Interventions that are Cost-Effective’ guidelines, the disability adjusted years of life lost 
averted by treatment were calculated and divided by the total cost of treatment.  The result 
was compared to the South-African Gross Domestic Product (GDP) per capita. 
Results 
Ten patients treated for Burkitt Lymphoma between 2005 and 2010 were included in the 
study.  The average direct cost was US$12829 per patient.  A trend was found for 
treatment of late stage disease to be more expensive than early stage disease, as well as 
a less favourable prognosis of late stage disease, as expected. A trend was also noted for 
the treatment of HIV infected children with Burkitt Lymphoma to fall well within the very 
cost-effective threshold. 
Cost related to general supportive care, was by far the largest contributing factor with 
hospitalisation contributing 49% of the total cost.  
The average cost to avert 1 DALY, was US$610.52, thus the average ratio to GDP per 
capita was 0.1:1, which indicates that the treatment of BL in South-Africa is well within the 
limits of being very cost effective (1:1). 
 
Conclusion 
The treatment of children with Burkitt Lymphoma in Tygerberg Children’s Hospital, South 
Africa is very cost effective, as it is well below the WHO-CHOICE threshold of very cost-
effectiveness. It is also very cost-effective to treat children with Burkitt Lymphoma who 
present with advanced disease as well as children with associated HIV infection.  
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Cost constraints should therefore not be a limitation to treating children with Burkitt 
Lymphoma, even if they present with advanced stage disease or HIV infection. 
Similar cost-effective studies in another type of paediatric cancer, private health sector or 
low-income countries, should be done to verify that the treatment of childhood cancers is 
very cost-effective.  




In lande met middel tot laer inkomste is die aantal pediatriese kankergevalle skaars in 
vergelyking met trauma en infeksie-siektes.  Daar is ‘n gebrek aan inligting in die literatuur 
oor die koste en koste-effektiwiteit van pediatriese kankerbehandeling, wat kan help met 
besluitneming oor die rasionele besteding van bronne.  Burkitt Limfoom (BL) is ‘n redelik 
algemene pediatriese kanker in Suid-Afrika.  Optimale behandeling en ondersteunende 
sorg van kinders met BL lei tot hoë genesingsyfers. 
Studie mikpunte 
Berekening van die koste om die verlies van een Ongeskiktheids-Aangepaste Lewensjaar 
(DALY) te voorkom deur die behandeling van kinders met BL in Tygerberg Kinderhospitaal 
en te bepaal of dit onder die drempel van koste-effektiwiteit val. 
Metodes 
Die studie is ‘n longitudinale, beskrywende oudit en koste-effektiwiteits analise. Data is 
ingesamel uit alle moontlike rekords van Tygerberg Kinderhospitaal en die totale direkte 
koste van behandeling en opvolg is bereken.  Deur die Wêreld Gesondheids Organisasie 
se ‘Choosing Interventions that are Cost-Effective’ riglyne te gebruik, is die verlies aan 
ongeskiktheids-aangepaste lewensjare wat voorkom is deur behandeling bereken en 
gedeel deur die totale koste van behandeling.  Die resultaat is dan vergelyk met die Suid-
Afrikaanse bruto binnelandse produk per kapita. 
Resultate 
Tien pasiënte wat behandel is vir BL tussen 2005 en 2010 is ingesluit in die studie.  Die 
gemiddelde direkte koste was US$12829 per pasiënt.  ‘n Neiging is gevind dat die 
behandeling van vroeë stadium siekte minder koste beloop as laat stadium siekte, sowel 
as ‘n swakker prognose geassosieer met laat stadium siekte, soos verwag. 
Die onkoste van algemene ondersteunende sorg, was by verre die grootste bydraende 
faktor en hospitalisasie alleen het 49% van die totale koste beloop. 
Die gemiddelde koste om 1 DALY te voorkom, was US$610.52 en die gemiddelde 
verhouding tot Bruto Binnelandse Produk was 0.1:1, wat aandui dat die behandeling van 
BL in Suid-Afirka gemaklik onder die bo-grens van hoë koste-effektiwiteit, wat 1:1 beloop, 
val.   
Gevolgtrekkings 
Die behandeling van Burkitt Limfoom in Tygerberg Kinderhospitaal, Suid-Afrika is hoogs 
koste-effektief, omdat dit ver onder die WGO-CHOICE riglyne se drempel van koste-
effektiwiteit val.  Dit bly ook koste-effektief, ongeag gevorderde stadium van siekte by 
presentering of ‘n positiewe HIV-status.  
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Koste beperkings behoort dus nie behandeling van kinders met Burkitt Limfoom te 
ondermyn nie, al presenteer hulle met laat-stadium siekte of ‘n positiewe HIV-status.  
Soortgelyke studies wat koste-effektiwiteit analiseer, behoort uitgevoer te word in ander 
tipes pediatriese kankers, die privaat sektor en in lande met lae-inkomste om te bevestig 
dat behandeling van kinders met kanker koste-effektief is. 
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1 Introduction 
In a difficult economic climate, I became aware of an increasing trend to guide resource 
allocations based on cost-effective decision making. Low to middle income countries are 
under pressure to allocate limited healthcare resources. Childhood deaths due to 
infectious diseases are common in these countries and often preventable with the correct 
treatment. (1)  In comparison, childhood deaths due to cancer are infrequent. There may 
be a public perception that the treatment of childhood cancer is expensive and that it 
carries a guarded prognosis despite treatment.  
South Africa is a Middle-income country(2), with the infrastructure and expertise capable of 
providing a high standard of care – which is likely to be expensive – but burdened with a 
high number of childhood deaths related to infectious diseases(1) and also faces this 
conundrum.  
 A utilitarian approach may prompt decision makers in such countries to divert resources 
away from cancer treatment, to more common, less costly diseases.   However, looking at 
the absolute cost of treatment is only a part of the answer and the WHO-CHOICE 
framework advises making decisions based on cost-effectiveness and suggests 
calculating the cost to avert one DALY and comparing it to the GDP per capita as an 
option. There is inadequate information available on the cost or the cost-effectiveness of 
treatment of diseases or disorders, which is why I decided to contribute to this field of 
study.  
Tygerberg Children's Hospital is a central referral facility with an Oncology Unit that uses 
standardised treatment protocols.  It keeps records of all treated children with the 
Tygerberg Hospital Children’s tumour registry which made it ideal for my study.  Burkitt 
Lymphoma is one of the most common paediatric cancers in SA and has a successful cure 
which made it a good subject for investigation.  
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2 Literature review 
2.1 Topics and Objectives of literature review 
- To describe the epidemiology of paediatric Burkitt Lymphoma (BL), including: 
 a)  The burden of disease globally and locally. 
b)  Peak age and stage of presentation, natural history and most common   
complications. 
- Research the current treatment protocols, the success rates and the most likely 
serious adverse events. 
- To determine the average life expectancy in South Africa and gross domestic product 
per capita. 
- Determine the standard framework to evaluate cost effective treatment and the 
disability weight allocated to BL. 
- Search literature for similar cost-effectiveness studies in childhood cancer, BL in 
particular, as well as childhood infectious diseases, for comparison.  We would take 
particular care to find studies performed in other middle- to low income countries. 
 
2.2 Population Statistics 
We found official reports of governments and United Nations through the internet search 
engine Google and yielded the required statistics. 
In South Africa, life expectancy at birth, according to the 2014 midyear analysis is  61 
years - 59.1 for males and 63.1 years for females(3).  The per capita Gross Domestic 
Product (GDP) for 2014 is US$5916.46 and the per capita GDP purchasing power parity 
(PPP) adjusted is US$12105.55(2).   
According to the Child Healthcare Problem identification programme, cancer is only the 
31st most common cause of death in South African children causing 0.7% of deaths(1), 
similar to other African countries. This is in contrast to first world countries where it is the 
2nd to 4th most common, causing 3% of deaths in USA and 15% in Scandinavian 
countries.(4–7)  The true incidence of paediatric cancers in African countries however, 
may be underestimated due to under-diagnosis, under-reporting and lack of cancer 
registries. 
2.3 Overview of Epidemiology, Staging, Treatment and Outcome 
Burkitt lymphoma is an aggressive form of Non-Hodgkin’s B-Cell Lymphoma (NHL). It 
usually presents primarily in the abdomen (60-80%) or head and neck region.(11,12)  With 
a replication index of nearly 100%, it is the fastest growing human tumour and if left 
untreated, will result in 100% mortality, usually within 4-6 months.(8) There are three 
clinical variants.  
Endemic BL occurs in children from equatorial Africa, Papua New Guinea and Brazil 
where malaria is common. It is strongly associated with Epstein Barr Virus (EBV) and 
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malarial infections.  In endemic areas, BL comprises roughly 50% of childhood cancers. 
(9,10) 
Sporadic BL occurs outside these areas, is rarely associated with EBV and forms 30-40% 
of paediatric lymphomas. (9,10) 
Immunodeficiency-related BL is mostly associated with HIV infection.  In Africa, the high 
prevalence of HIV has only caused a gradual increased incidence of paediatric BL, 
possibly attributable to the poor survival rate of African children born with HIV. (9,10) 
This lymphoma is most common in children aged 3–12 years, the incidence peaks at 6–8 
years and is more common in boys than in girls.  In African countries, 60-70% of patients 
present with stage 3 disease.(11,12)  
The St. Jude staging system for NHL guides prognosis and treatment decisions.  Stage I 
and II disease are fairly well localised lesions that do not involve the central nervous 
system (CNS), bone marrow or thoracic cavity.  Stage III is non-resectable disease with 
extensive spread or thoracic cavity involvement, while stage IV indicates CNS or bone-
marrow involvement greater than 25%.(13) 
Investigations required for diagnosis and staging include biopsy for histology and 
immunocytological analysis, full blood count and film, as well as liver function tests and 
urinalysis, computerised tomography (CT) scans of chest and abdomen, bone marrow 
aspirates and cerebrospinal fluid evaluation.  In low-resource settings with a high 
incidence, fine needle aspirate with cytology, chest X-ray and abdominal ultrasound may 
have to suffice in the place of superior investigations. 
The long term cure and survival rate for BL varies between 30-50% in low-income African 
countries, using single or low dose chemotherapy agents and roughly 90% in the first 
world setting, using high dose chemotherapy and providing optimal supportive care.  
Survival is negatively impacted by advanced disease at diagnosis (Stage III-IV) and HIV 
co-infection.(14–16) 
Complications often arise and can either be a result from the tumor, associated co-
morbidities, surgery or chemotherapy.  Important tumor- related complications include 
respiratory obstruction or paraplegia from para-spinal tumor compression, while mucositis, 
infections, cytopenias, electrolyte disturbances and tumor lysis syndrome often occur 
during treatment.   
The chance of relapse after 1 year event free survival is less than 5%, while relapse after 5 
years is extremely rare.(17) 
The incidence rate of BL in South-African children (<15 years), is approximately 0.1 per 
100 000 per year. The sporadic form of BL is the most common type seen at Tygerberg 
Hospital Oncology unit. (18–20)  Burkitt Lymphoma is one of the most common paediatric 
cancers in South Africa, comprising roughly 40% of lymphomas, which is ranked the 
second most common cancer, behind leukemia.(4,16,18)  
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 The LMB 96 protocol is the treatment regimen of choice in South Africa and a recent 
study showed a 77% cure rate in HIV-uninfected children, but only 27% in HIV-infected 
children (60% overall). (14)  The higher mortality rate in the HIV-infected group was 
attributed to poor general health, low CD4 counts and frequent tuberculosis (TB) co-
infection. Stage of disease and site of presentation were independent predictors of poor 
outcome.  The study did note a trend that HIV-positive children were more likely to have 
CNS involvement. (14)  A similar study conducted in Uganda (which is an endemic area 
where less aggressive chemotherapy is used) also reported a much higher mortality rate 
among HIV-positive children than HIV-negative children, in spite of similar objective 
tumour responses. (15)  This study did find HIV-positive patients to present with more 
advanced disease and more CNS involvement, but did not mention co-infection or CD4 
count.(15)   
The LMB 96 treatment regimen groups patients into 3 categories(21,22):  
Group A comprises of Stage I and abdominal Stage II disease that is completely 
resectable.  After resection, this group receives two cycles of chemotherapy (COPAD). 
Group B consists of patients with non-resectable disease in any stage, but with no CNS 
involvement and less than 25% bone marrow (BM) involvement.  These patients receive 
an initial cycle (COP), followed by two induction cycles (COPADM) and two consolidation 
cycles (CYM), but would be transferred to group C if they still have residual disease after 
the first consolidation cycle. 
Group C consists of patients with CNS disease and/or BM involvement of greater than 
25%.(21,22)  They receive initiation and induction cycles as above, with consolidation 
cycles (CYVE) and four maintenance cycles.  Patients with CNS involvement also receive 
intra-thecal therapy, as well as added methotrexate between consolidation treatments.  
Side effects associated with treatment of BL may lead to prolonged hospital admissions, 
added investigations and medication, which increases the cost of treatment. (19,20) 
Neutropenic sepsis, mucositis, gastro-enteritis and tumor lysis syndrome are the most 
common associated side effects seen at Cape Town pediatric oncology units. (19,20) 
2.4 Cost-effective analysis 
Guidelines to determine the cost and evaluate the cost-effectiveness of treatment is 
stipulated in the WHO’s ‘Guide to cost - effectiveness analysis and ‘Burden of Disease 
reports.(23,24)  They suggested the detailed calculation of all expenses related to 
treatment and to measure these costs against Years of Life Lost (YLL), Disability Adjusted 
Life Years (DALYs) and the per capita Gross Domestic Product (GDP) of the country to 
help guide important decisions regarding the optimal application of resources.  The per 
capita GDP serves as an indication of what a country can afford per citizen and of the 
earning potential gained averting DALYs. The Global Burden of Disease working group 
has set the Disability Weight for Non-Hodgkin’s Lymphoma at 0.09.(23,24) 
Finding similar studies relating to the cost effectiveness of treating cancer proved 
challenging due to a variety of key phrases being used in the titles and headings.  Key 
words used in the PubMed and the SUNLIS searches included: ‘Burkitt’s or Burkitt 
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Lymphoma’, Non Hodgkin lymphoma, ‘cancer’, ‘treatment’, ‘children’, ‘cost effective’, ‘cost 
analysis’, ‘South-Africa’, ‘developing countries’.  I also scrutinised the references of closely 
related publications. 
Russel et al. (2013) conducted a systematic review aimed at identifying areas to improve 
resource efficiency in treating various types of pediatric cancer, specifically in developed 
countries. The average cost for the in-patient care of a pediatric cancer patient (primary 
episode) in the United States of America (USA) was estimated at $40 400 and rising 
sharply. For children with leukemia or CNS tumours the average direct treatment-related 
cost was US$89 000 for survivors and US$236 000 for those that died.  The authors 
estimated indirect cost to the family of a patient at US$3725 to US$4648 – and considered 
it a minor relative cost, at less than 10% of total expenditure. The literature revealed a 
large heterogeneity in the quality of the studies and was mostly aimed at establishing the 
cost to benefit ratio of single additional interventions.(25,26)   
Norum et al. (1996) did a cost-effectiveness study of Hodgkin’s Lymphoma (HL) treatment 
in adults in Norway.  They calculated the average healthcare cost (including indirect costs) 
at US$18 768 in 1994.  The Quality Adjusted Life Years (QALY) gained were determined 
on an individual patient basis by a panel of experts that estimated their life expectancy and 
quality of life. The subsequent cost of one QALY was US$1990.(27)   
Stefan and Stones (2009) conducted a calculation of the cost of primary treatment and 
two-year follow-up of Hodgkin Lymphoma at two pediatric oncology centres in South 
Africa.  They included the cost of all investigations and medication, but excluded costs 
related to hospitalisation, staff salaries and disposables.  They reported the treatment cost 
of stage II HL as US$6647.(28) 
Bhakta et al. (2011) aimed to create a framework to determine cost-effectiveness 
thresholds for pediatric cancer using WHO and Global Burden Study of Disease 
guidelines.  Using information from 2 treatment outcome studies that also provided 
information regarding cost of treatment – Howard et al. (2004) and Hesseling et al. (2009) 
- they conducted cost-effectiveness analysis of  Acute Lymphocytic Leukaemia(ALL) in 
Brazil (middle-income country) and BL in Malawi (low-income) as examples.  In Brazil the 
average direct cost of staging, treatment and 1 year follow-up for each child with ALL was 
calculated as US$16 700.  They did not mention whether this included cost related to the 
initial workup and diagnosis at presentation.  The cost per DALY gained was US$447.  In 
Malawi, they only included the cost of medication used in the less intensive chemotherapy 
regimen – which was less than US$50 per patient, but in all likelihood represented only a 
fraction of the total cost of care. The cost for DALYs gained was compared to the per 
capita GDP for each respective country and found to be much lower than the 1:1 
threshold, which defined the treatment as very cost effective.  The amounts used for the 
GDP per capita was Purchasing Power Parity adjusted, although they refer to it as per 
capita GDP.(29–31) 
Comparatively, cost analysis studies of infectious diseases have shown much lower costs 
per case, as expected. The total direct cost of treating community acquired pneumonia in 
pediatric patients in the South African public sector was calculated by Kitchin et al. (2011) 
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at US$639.06 for HIV infected children and US$399.45 for HIV negative children.(32)  The 
cost of tuberculosis treatment per patient is estimated at US$100-500 in high-burden 
countries and US$2000 in developed countries.(33,34) 
2.5 Discussion of literature review 
The incidence of childhood cancer is rare (5), but is proportionally still a major cause of 
mortality in developed countries.(4–7)  However, it is overshadowed by trauma and 
infectious diseases in middle and low-income countries. (1) The burden of childhood 
cancers is possibly underestimated due to the lack of cancer registries or active reporting.   
Burkitt Lymphoma (BL) is a common paediatric cancer in South Africa. (4,16,18)  Optimal 
treatment and supportive care of BL (as seen in developed countries) can lead to high 
cure rates and low relapse rates. (14–16) 
Literature suggests that cost of treating childhood cancer is markedly higher in developed 
countries compared to developing countries. (29–31)   This difference may be due to 
increased costs associated with in-hospital care and less restricted use of investigations 
and interventions. Even in developing countries, the cost of treatment of cancer is still very 
expensive when compared to the treatment of infectious diseases.(33,34) This highlights 
the importance of informed decision making regarding the allocation of healthcare 
resources in middle- and low income countries.  
There are only limited research studies with uniform designs to determine the cost or cost-
effectiveness of cancer treatment, especially in limited resource settings. Following a 
comprehensive literature search, we found no published cost analysis studies assessing 
the total direct cost of treating Burkitt Lymphoma, or cost-effectiveness analyses of cancer 
treatment in South Africa. 
 
3. Research Justification 
I chose a relatively common paediatric cancer for a pilot study, with a standardised 
treatment regimen that is well described in literature.  
3.1 Research question 
Is the treatment of children diagnosed with Burkitt Lymphoma cost effective in a middle-
income country, such as South Africa? 
3.2 Hypothesis 
Treating Burkitt Lymphoma in South Africa (a middle-income country) is very cost-effective 
and the null-hypothesis is that it is not cost-effective to treat Burkitt Lymphoma in South 
Africa.   
3.3 Objectives 
- Calculate the cost per patient treated for Burkitt Lymphoma at Tygerberg Children’s 
Hospital. 
- Determine the average disability adjusted life years gained by treating a patient with 
Burkitt Lymphoma. 
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- Calculate the cost per DALY gained. 
- Determine the ratio of cost per DALY to the gross domestic product per capita in South 
Africa. 
- Compare the cost per DALY to GDP per capita ratio to the World Health 
Organisation’s Choosing Interventions that are Cost Effective (WHO-CHOICE) 
threshold of cost effectiveness. 
4. Methods 
4.1 Setting 
Tygerberg Children’s Hospital is a 308 bed academic hospital in Cape Town, South Africa. 
It includes a dedicated Paediatric Oncology Unit and receives paediatric referrals from the 
Western Cape for the diagnosis and treatment of cancer. 
4.2 Literature review 
I performed a Boolean search of Pubmed Library and Stellenbosch University Library and 
Information Services (SUNLIS) using keywords:  "burkitt's lymphoma", “burkitt lymphoma” 
AND "children" in combination with  "epidemiology", “staging”, “treatment outcome” and 
limited results to the  last 10 years.  This yielded four large reviews of recent BL-related 
literature, of which three included African data. The reviews were published in The 
Lancet(2012)(8), African Health Sciences(2007)(9) and the British Journal of 
Haematology(10) respectively and aimed to provide an overview of the disease and 
unravel the link between the epidemiology and the etiology of BL.  They also provided an 
overview of staging, prognosis, treatment options and outcome.  These reviews were 
thoroughly researched and supported each other’s findings.  As such, they form the basis 
of this section.   However, I performed additional sub-themed searches and studied some 
of their listed references to provide confirmation or more clarity on individual subjects and 
for information specific to South Africa (SA) and Tygerberg Hospital (TBH).  
4.3 Study Design 
The study is a retrospective, longitudinal descriptive audit and cost-effectiveness analysis. 
4.4 Inclusion and exclusion 
Paediatric patients (age ≤15years), who were diagnosed and treated for Burkitt Lymphoma 
at Tygerberg Hospital (TBH) between 2005 and 2010 were identified through the 
Tygerberg Hospital Children’s Tumour Registry.  The timeframe for the search was 
established to optimise the eligible patient numbers and availability of financial records 
(which are destroyed after 10 years), while keeping the change in treatment protocols and 
item prices relatively small.  It also allowed for completion of the full course of treatment 
and a 2 year follow-up period, to establish whether successful cure was accomplished.  
Relapse of BL is highly unlikely beyond 2 years from remission. (17) 
4.5 Data collection 
We retrieved patients’ treatment folders from the oncology ward. Additional clinical 
records, containing nursing notes, prescription charts, microfilms and other clinical data, 
were obtained from the department of medical records. We also collected data from 
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hospital-based laboratory and radiology records.  This was done to ensure completeness 
of collected data.  
 Data collected included: 
- Patient details (age, sex, weight, date of diagnosis).  
- Disease group of each patient (assigned to each patient as per the LMB 96 protocol 
into Group A, B or C). (See Appendix 1) 
- The number of admission days, as well as the specific ward of admission.  In TBH, 
different wards have different levels of care, implying different cost of admission. 
- The number of outpatient visits. 
- Chemotherapy received was recorded on a separate chemotherapy documentation 
sheet. 
- Surgical procedures performed, as documented in clinical records. 
- Minor surgical procedures, as documented in clinical records, consisting mainly of 
central line insertions or biopsies, as categorised in UPFS. 
- Imaging studies performed and the results thereof; obtained from patient folders.  
Studies from 2007 were reconciled with the I-site Digital Imaging Database.  Prior to 
2007, no reconciliation was possible since digital imaging was only implemented at 
TBH at that stage and no hard copies were kept for more than 5 years. 
- Laboratory investigations performed and the associated results: obtained from the 
clinical records and reconciled with data from the National Health Laboratory Service 
(NHLS) database.  Results may have cost implications in some cases – for instance, a 
positive blood culture is more expensive than a negative culture, due to drug sensitivity 
testing.    
- We identified medication, fluids, blood products and supplementation received from 
treatment charts and included all routes of administration. Both inpatient and 
outpatient scripts were taken into consideration. 
- Auxiliary services rendered, i.e. physiotherapy were not recorded, as it did not affect 
the cost of admission or outpatient appointments. During an outpatient visit or hospital 
admission the patient is charged the highest rate, which in all cases would have been 
the charge for the paediatric specialist. 
- Disposables, for example syringes, needles, etc. were not collected as it is 
incorporated into the cost of an admission, outpatient visit or procedure. 
4.6 Data capturing 
Data were collected on a case recording form.  We allocated a case number to each 
patient.  Data was subsequently transcribed to an Excel spreadsheet and cost calculations 
done.   
4.7 Price calculation 
Patients are charged different rates according to their income category in South African 
public sector hospitals. Children under the age of 5 years receive free medical care. A 
significant percentage of patients with Burkitt Lymphoma are under the age of 5 years, or 
their caregivers fall in lower income categories, and are then only charged a small portion 
of actual costs. Each patient was assigned to the full paying category, to estimate the true 
cost accrued to treat children with Burkitt Lymphoma. (See Appendix 3) 
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The collected data was tabled and the combined costs calculated from the price 
catalogues, as it were on 1 April 2014: 
- The Uniform Patient Fee Schedule, procedure code and radiology code for the 
provincial health system. From the codes on the procedure code forms, the costs of 
procedures, admissions and radiological investigations were determined. 
- The TBH pharmacy price list. 
- The TBH NHLS tariff rates for state patients. 
- The TBH department of Human Nutrition’s price list of supplemental feeds.  
- The Western Province Blood Transfusion Service’s price list for state patients. 
The direct non-medical costs (transport costs, meals of caregivers in hospital, etc.) and 
cost associated with loss of productivity of parents was not included. These costs were not 
included as this is a retrospective study and no data regarding the above was available. 
The total direct cost related to treating children with BL were then calculated per patient in 
South African Rand (ZAR) before conversion to US Dollars (US$), using the average 
conversion rate for 2014.(35)   
4.8 Cost-effectiveness calculation 
To calculate the DALYs gained by treatment per cured patient, we subtracted the age at 
diagnosis from the life expectancy of the applicable gender to determine the total years of 
life lost (YLL) averted.  Then we calculated Years of life with disability (YLD) during- and 
after treatment by multiplying the appropriate disability weight (DW) with the duration (in 
years) of disability. In BL the duration of treatment was used as the duration of disability. 
For permanent disabilities, it is calculated as the period from diagnosis until end of 
estimated life expectancy. Disability weight is a set severity weight that measures the 
valuation of the loss of healthy life for each clinical condition, as determined by the Global 
Burden of Disease working group.(23,24) When more than one disability co-existed, the 
combined disability weight is calculated using the formula:  DWcombined = 1 - (1 - DWa) 
(1 - DWb).  Since cancer in the presence of HIV positivity is an acquired immune 
deficiency syndrome(AIDS)-defining disease and all children were started on anti-retroviral 
therapy(ART) during treatment, the DW used were the ‘AIDS on ARTs’ average as 
obtained from the WHO guidelines.(23,24)  The DALYs gained is the difference between 
the YLL averted and the YLD.  A patient that died due to BL had no DALYs gained, 
therefore to determine the average DALYs gained per patient, the sum of the DALYs of 
patients that survived, were divided by the total number of patients in the study.  The ratio 
between the average cost to avert 1 DALY and the RSA GDP per Capita is then 
calculated. 
We obtained the following variables used from literature: 
- RSA life expectancy (male) (3): 59.1yrs 
- RSA life expectancy (Female) (3): 63.1yrs 
- Disability weight (BL) (24): 0.09 
- Disability weight (AIDS on ARV’s) (24): 0.167 
- Disability weight (paraplegia) (24): 0.57 
- RSA Per Capita GDP (2014) (2): US$5916.46 
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- 2014 average South African Rand ratio US$ = 1:0.0923(35) 
4.9 Statistical Analysis 
This was a novel, retrospective, descriptive study regarding a rare condition and was not 
powered for in depth statistical analysis.  Where appropriate, the means, medians and 
ranges were used to summarise and describe the results.  Statistics and graph preparation 
were performed using Statistica 12 and Microsoft Excel 2010. 
4.10 Ethical considerations 
Ethical clearance was obtained from the University of Stellenbosch Health Research 
Ethics Committee (HREC 2; Ethics Reference: S13/10/186).  This was a retrospective 
study with influence the care of the participants, and a waiver of consent was granted, with 
the provision of identity protection.  I also obtained approval from the TBH Senior medical 
superintendent to conduct the study. 
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5. Results 
5.1 Patient Demographics 
Eleven children were treated for BL at Tygerberg Children’s Hospital Oncology Unit 
between 2005 and 2010.  One patient was excluded due to missing hospital records and 
clinical notes. Nine patients were male and one female. The youngest was 2 years and 3 
months, while the oldest was 10 years and 6 months at the time of diagnosis.  The median 
age was 6 years.  Five out of the 10 patients included were HIV positive.  None of the HIV 
positive children was on antiretroviral therapy, or virally suppressed at diagnosis. 
 
Figure 1:  Breakdown of retrospective recruitment and follow-up of patients diagnosed with 
Burkitt Lymphoma between 2005 and 2010 at Tygerberg Children’s Hospital in South 
Africa. 
 
5.2 Treatment and Outcome 
Five of the patients treated for Burkitt Lymphoma died and five patients were cured. All five 
patients that survived completed 2 year follow up period at Tygerberg Hospital and there 
were no relapses documented. 
5.2.1 Patients in disease group A 
After diagnostic and staging investigations, two patients were diagnosed with resectable 
abdominal disease (Stage II) and assigned to LMB 96 treatment protocol Group A.  For 
these patients treatment included surgical resection via laparotomy and 2 cycles of 
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chemotherapy, consisting of vincristine, cyclophosphamide, prednisolone and doxorubicin 
(referred to as COPAD in the LMB 96 protocol). (See Appendix 2) 
The first patient was a 2-year-old boy.  He was diagnosed as HIV positive, with a CD4 
count of 12.7% (absolute count 778 cells/mm3) and a viral load of log 5.87 (740654 
copies/ml).  He suffered tumor lysis syndrome, liver failure and febrile neutropenia as 
complications during therapy.   He required 35 days of admission to a tertiary care ward 
and attended eight outpatient visits.   
The second was a 10 year old, HIV-negative boy.  He suffered no complications during 
treatment, required 27 days of tertiary inpatient care and attended 12 outpatient visits. 
5.2.2 Patients in disease group B 
Four patients had non-resectable disease, which spared the central nervous system (stage 
III) and bone marrow, and were assigned to treatment protocol Group B.  Two of these 
children died due to septicaemia. Both were HIV negative.  
The first patient, a 2-year-old boy, developed bowel perforation due to an abdominal 
tumour and subsequent gram-negative septicaemia.  He was taken to theatre for a 
laparotomy and received broad-spectrum antibiotics, but died on the 12th day in hospital (2 
days in secondary level ward, 9 days in a tertiary ward and 1 day in the paediatric 
intensive care unit (PICU).   
The second patient was a 7-year-old boy who died during chemotherapy, after 35 days in 
the tertiary care ward and 3 days in the PICU.  He suffered repeated episodes of febrile 
neutropenia and sepsis. Treatment for this patient included a laparotomy and numerous 
blood transfusions to the value of US$11232.   
The two surviving patients from this group successfully completed five cycles of 
chemotherapy (1 initiation- , 2 induction- and 2 consolidation cycles) and were cured.  The 
first was an HIV negative 6-year-old boy.  He suffered from treatment-related 
complications, which included febrile neutropenia, tumor lysis syndrome, mucositis and 
reversible renal failure.  He spent a total of 39 days in a tertiary care ward and had 14 
outpatient visits.   
The fourth patient was a 7 year old HIV positive boy, with a CD4 count of 28% (469 
cells/mm3) and a viral load of log 4.4 (25000 copies/ml).  He spent 48 days in the tertiary 
care ward and had 10 outpatient visits. He had reversible renal failure and mucositis as 
complications.   
5.2.3 Patients in disease group C 
Four patients had disease involving the central nervous system and bone marrow and 
required treatment as per the Group C treatment plan.  Only 1 Group C patient was 
successfully cured: a 10-year-old HIV positive boy who presented with lower limb 
paraplegia (L5/S1level).  He had a CD4 count of 24% (304 cells/mm3) and a viral load of 
log 4.6 (40000 copies/ml). He spent a total of 100 days in hospital (88 days in the tertiary 
care ward and 12 in a secondary care ward); he also had 15 outpatient visits. The lower 
limb paralysis remained despite successful treatment.   
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Of the Group C patients with unsuccessful treatment outcomes, the first was a 2-year-old 
girl who demised after only 4 days in the tertiary care ward.  She was HIV positive and 
presented with disseminated BL. Her CD4 count was 27.7% at diagnosis (absolute count 
778 cells/mm3), but no viral load was requested at that time. She died in the theatre 
recovery room after thoracic biopsies in theatre; the diagnosis of Burkitt Lymphoma was 
made after she succumbed, on these biopsies.  Post-mortem examination cited cardiac 
failure as the most likely cause of death.   
The other two patients in Group C were boys and presented with extensive disease, which 
included neurological manifestations.  Both suffered from tumor lysis syndrome, febrile 
neutropenia and sepsis during treatment and required intensive treatment and care.  One 
was 5 years old and HIV positive with a CD4 count of 10% (318 cells/mm3) at diagnosis, 
but no viral load was performed.  He died after 57 days (2 days in the secondary care 
ward, 53 days in the tertiary care ward and 2 days in PICU), while the other boy was 6 
years old, HIV negative and demised after 21 days (19 days in the tertiary care ward and 2 
days in PICU). 
In summary: both patients with Group A disease were cured, while 2 out of 4 patients 
assigned to Group B and 3 out of 4 assigned to Group C succumbed before completion of 
treatment.  The only cured Group C patient was paraplegic because of spinal involvement.  
This was the only disease-related permanent disability that occurred in the 5 survivors. 



















A Cure 10.5 Negative 27 4184.73 0 6687 
A Cure 2.58 Positive 35 5424.65 0 8335 
B Cure 5.58 Negative 39 6044.61 186 10976 
B Cure 6.92 Positive 48 7439.52 0 11609 
B Death 2.25 Negative 12 2285.73 1887 4856 
B Death 7.58 Negative 35 7546.91 0 23793 
C Cure 10.16 Positive 100 14739.56 465 25817 
C Death 6.25 Negative 21 4359.65 11196 10764 
C Death 2.92 Positive 4 619.96 2985 1839 
C Death 5.75 Positive 57 9810.87 0 23616 
Mean   6.05   37.8 6245.62 1671.9 12829 
Table 1: Summary of demographics and the two most significant components of cost 
calculation per patient. 
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5.3 Cost calculation 
Of the total direct cost to treat these 10 patients, admission costs, which represented the 
cost of clinical care, staff salaries and equipment maintenance, were by far the largest 
proportion, with each patient spending an average of 38 days as an inpatient. This 
amounted to US$6245.81 per patient and effectively contributed 49% of the total cost 
(figure 2).  The second largest contributor was the cost of blood product transfusions, 
which contributed 16% and amounted to an average of US$2115.79 per patient.  The cost 
of blood products was inflated by the fact that leucocyte depleted blood was indicated.   
 
Figure 2:  Average cost (US$) of each contributing component per patient.   
 
Laboratory investigations comprised 13% of costs. The most costly laboratory investigation 
was a full blood count (with and without a differential cell count).  A total of 320 counts 
were requested and amounted to US$1917. This was followed by serum calcium-, 
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Figure 3:  Medication cost breakdown.   
Medication (on average US$1268.20 per patient) was responsible for a proportion of 13% 
of the total cost (figure 3).  Chemotherapy (36%) contributed most to the bulk of 
medication- related cost, followed by intravenous (IV) fluids (28%) (Figure 3). Intravenous 
fluids included the following: crystalloids and total parenteral nutrition (blood products 
excluded). Oral rehydration solution and nutritional supplements (Pediasure, Ensure, 
Nutren Junior, Nutren Active and Peptomen Junior) were classified as oral fluids. Oral 
nutritional supplements made up the bulk of the cost of oral fluids and more than half the 
cost of IV fluids was due to total parenteral nutrition.  Oral medication included anti-
retroviral therapy.  'Other' consisted of topical, otological, optical and rectally administered 
medication. 
Computed tomography (CT) and Magnetic resonance imaging (MRI) scans required for 
diagnosis and staging were the most expensive imaging investigations. Imaging 
investigations contributed 7% of the total cost (figure 2).  Surgical procedures included four 
laparotomies and made up only 4% of the total expenses.  Outpatient follow up visits were 
inexpensive and only contributed 1%. 
The total direct cost related to treatment ranged from US$1838.60 to US$25817.21. This 
amounted to an average total direct cost of US$12829.07 per patient. The rapid course of 
one patient’s extensive disease resulted in the lowest cost of treatment in this cohort at 
US$1839, as this patient died within 4 days of presentation. The patient that amassed the 
highest cost in the cohort (at US$25817) spent a total of 100 days in hospital. He survived, 
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Patient 1 2 3 4 5 6 7 8 9 10 Total US$ 
Group B C B B C C A B C A  
Outcome Survived Died Survived Died Survived Died Survived Died Died Survived  
Admission 6064 622 7464 2293 14787 9845 5442 7571 4374 4198 62661 
Transfusion 0 0 466 0 1894 4454 186 11232 2995 0 21227 
Lab tests 2697 341 1774 1354 2525 2579 1237 2038 1310 602 16457 
Radiology 518 519 546 518 2942 1818 418 784 364 878 9305 
Procedure 173 304 86 593 657 917 571 674 244 571 4790 
Chemo 553 0 561 23 1534 1003 153 341 302 75 4545 
IV Meds 270 47 211 71 574 1291 72 726 514 25 4509 
IV Fluids 1 0 1 0 14 10 4 25 10 0 3604 
Follow up 332 6 212 17 265 1668 48 366 665 25 1545 
PO Fluids 367 0 262 0 393 0 210 0 0 314 65 
PO Meds 19 6 30 2 287 90 11 88 22 17 570 
Other meds 18 0 34 1 30 20 8 25 0 4 140 
Total US$ 11011 1845 11647 4871 25901 23693 8362 23870 10799 6709 129417 
 
Table 2:  Breakdown of direct cost (US$) per patient (each numbered 1-10, disease group 
indicated as A, B or C, as well as the patient outcome (survived or died)) and contributing 
cost components.                                                                                                             
[Lab: laboratory; chemo: chemotherapy; IV: intravenous; meds: medication; PO: per os] 
The management and treatment of a child assigned to Group C was the most expensive at 
US$15508.91, followed by Group B (US$12808.28).   Group A was the least expensive 
with an average cost of US$7510.98 per patient(figure 5).   
 




































Figure 4: Box-plot comparing the cost (US$) of Burkitt Lymphoma treatment per assigned 
treatment protocol group.  Median and range are shown.  All patients were included. 
Treating a HIV positive patient was more expensive than treating an HIV uninfected child, 
with an  average cost of US$14243.10 and US$11415.04 respectively (figure 5). Costs 
directly related to HIV diagnosis and treatment (HIV Elisa, CD4 counts, viral load, anti-
retroviral drugs) alone can not account for the cost difference as this amounted to only 
$101,on average, per HIV positive patient. There was no notable trend for patients with a 










A Survived 2.58 Male 12.7 3.04 
B Survived 6.92 Male 28 4.4 
C Survived 10.16 Male 24 4.6 
C Died 2.92 Female 27.7 Not done 
C Died 5.75 Male 10 Not done 
Table 3:  Disease group; CD4 count and  viral load for HIV positive children with Burkitt 
Lymphoma 




































Figure 5: Box and whisker plot comparing the cost (US$) of Burkitt Lymphoma treatment 
per HIV status. The median and range are shown. All patients were included. 
A trend was seen for young age (less than 3 years old) to be associated with a lower cost 
(figure 6).  This is likely because in this cohort, these patients either presented at an early 
stage, or died soon after presentation.  This data should be interpreted with care, due to 
the small sample size. 
 
Figure 6:  Scatterplot of age compared to cost (US$), showing a moderate, but non-
significant positive correlation. All patients were included. 
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5.4 DALYs gained calculation 
No DALYs were gained for patients that demised in spite of treatment and they required no 
further calculation.  The cost of their treatment is compared to the DALYs gained in cured 
children. 
For cured patients the Years of Life Lost averted were high (48.6 to 56.5 years), as 
expected. The disability weight during treatment and after cure were different, since the 
disability weight due to BL falls away at cure, but the disability weight for paraplegia and 
HIV persists for life. The final date of chemotherapy or hospital admission (whichever 
came last) was designated as the date of cure.   
In the following examples, patient 5 (HIV positive patient, with Group C disease, who 
survived with paraplegia) will be used in the calculations. 
Example: Calculation of Averted YLL = Life expectancy (male) – Age at date of admission  
           = 59.1 – 10.2   
           = 48.9 years 
 
The Years of Life with Disabilty (YLD) during treatment, was almost negligable in all cases, 
given the  relative short time on treatment, when compared to the expected life expectancy 
of a person.  This held true even in the most extreme case when combined DW’s were 
used (maximum 0.34 years).  
Example: Duration of disability during treatment   
      = Date of admission – date of discharge/last chemo   
= 0.51 years 
 
Example: Combined DW of lower limb paraplegia, AIDS on ARV's and Burkitt Lymphoma 
(as a proportion of combined DW) 
= 1 – (1-DWhiv)(1-DWpara)(1-DWbl)    
= 1 – (1-0.167)(1-0.57)(1-0.09)   
= 0.67 
 
Example: Years of life with disability during treatment  
= Duration of disability during treatment x Combined DW during treatment 
= 0.51 x 0.67  
= 0.34 years 
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Where applicable, the DW after treatment were due to HIV status and paraplegia, which 
was the only permanent complication in this study group.   
Example: Combined DW of HIV infection and lower limb paraplegia 
= 1 – (1-DWhiv)(1-DWPara)  
= 1 – (1-0.167)(1-0.57)   
= 0.64 
YLD after treatment were fairly low as well, even for HIV positive patients (max 9.45years). 
It was notably high only for the patient with permanent lower limb paraplegia. His 
calculations were used as examples, since it was the most complex. 
Example: Calculation of YLD after treatment  
= Averted YLL after treatment x Combined DW  
= 48.43 x 0.64   
= 31.1 years 
 
Calculated DALYs gained for cured patients ranged from only 17.51 for the patient with 
paraplegia (due to the high YLD) to 53.20 for an otherwise well patient.    
Example: Total YLD 
 = YLD during treatment + YLD after treatment  
= 0.34 + 31.1 
  = 31.4 years  
 
Example: Gained DALY   
= Total averted YLL – total YLD  
= 48.9 – 31.4 
= 17.5 years 
  























A Cure 48.6 0.09 0.01 Nil 0.00 0.00 0.00 
48.6 
137.60 0.02 
A Cure 56.52 0.24 0.02 HIV 0.17 9.42 9.45 
47.07 
177.06 0.03 
B Cure 53.52 0.09 0.02 Nil 0.00 0.00 0.02 
53.5 
205.15 0.03 
B Cure 52.18 0.24 0.06 HIV 0.17 8.67 8.73 
43.45 
267.20 0.05 
B Death 0 0 0 0 0 0 0 
0 
n/a n/a 
B Death 0 0 0 0 0 0 0 
0 
n/a n/a 
C Cure 48.94 0.67 0.34 
Paraplegia 
and HIV 0.64 31.08 31.43 17.51 1474.14 0.25 
C Death 0 0 0 0 0 0 0 
0 
n/a n/a 
C Death 0 0 0 0 0 0 0 
0 
n/a n/a 
C Death 0 0 0 0 0 0 0 
0 
n/a n/a 
Total n/a 259.76 n/a 0.45 n/a n/a 49.17 49.63 210.1 n/a n/a 
Result          610.52 0.1 
 
Table 4:  Summary of DALYs gained and ratio between DALYs gained and per capita 
GDP per patient. The US$/DALY and US$/DALY:GDP/Capita columns indicate values per 
patient but the calculated result shown takes cost of treating patients who died into 
account. (YLL: Years of life lost; DW: disability weight; YLD: Years of life with disability; 
DALY: Disability adjusted life year; GDP: Gross domestic product per capita; n/a: Not 
applicable) 
 
The DALYs gained for each patient was calculated and added (Table 4).  The total cost of 
treatment (Table 2) was then divided by the total DALYs gained which yielded the average 
cost to avert one DALY.  The result was that the average cost was $610.52 to avert one 
DALY.   Earlier stages of disease were much more cost-effective to treat than late stages 
of disease, due to the shorter duration of treatment, lower cost and improved outcome.  
The average cost to avert one DALY was $157.01, $528.47 and $3542.19 respectively for 
groups A, B and C (Figure 8). In HIV positive patients, it cost US$659.22 to avert one 
DALY, compared to US$559.01 to avert one DALY in HIV negative patients. 





























Figure 7: Box plot of US$ per one disability adjusted life year gained categorised by 
assigned treatment protocol group. All patients included.  Median and range are shown 
(DALY: Disability adjusted life year; US$: United States of America Dollar) 
The ratio of cost to avoid one DALY to GDP per Capita was 0.1:1. Therefore the treatment 
of Burkitt Lymphoma falls well within the very cost effective range according to the WHO 
CHOICE criteria(<1:1).(23)  If subsets were formed based on assigned treatment groups, 
the ratios would be 0.03:1 for Group A, 0.09:1 for Group B and 0.60:1 Group C.  Thus, the 
treatment of BL Group C disease is still in the very cost effective range. When comparing 
HIV positive and HIV negative patients, the cost to avoid 1 DALY to GDP per capita ratios 
were 0.11 and 0.09 respectively, indicating that even treating HIV positive patients with BL 
is also well within the very cost effective range. 
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6. Discussion 
6.1 Summary of findings 
Ten patients were diagnosed and treated for BL at Tygerberg Hospital from 2005 – 2010. 
The average direct cost of management was US$12829 per patient.  The treatment 
resulted in a 2-year event-free survival rate of 50%.   
The findings indicate that the treatment of BL at Tygerberg Children’s Hospital is very cost 
effective, by a large margin.  The average cost to avert 1 DALY, was US$610.52, thus the 
average ratio to GDP per capita was 0.1:1.  Despite the higher cost and poor prognosis of 
advanced disease, the treatment of these children, with a ratio of 0.6:1, is still well within 
the 1:1 WHO-CHOICE threshold of very cost-effectiveness (1US$ per 1 DALY gained to 
GDP per capita ratio). (23) Treating HIV infected children with Burkitt Lymphoma was also 
shown to be very cost-effective with a US$ per DALY gained to GDP per capita of 0.11:1. 
6.2 Comparison to previous studies 
The cohort compares very well to the data on sporadic BL obtained in previous reviews(8–
10) in terms of age, stage of presentation and complications due to disease and treatment.  
The cure and survival rate is also similar to data from a previous study done in South 
Africa,(14) which is quite assuring as it indicates that this study was not done on a biased 
sample.   
Due to the paucity of cost-effectiveness studies in BL, we compared our results to other 
childhood cancers.   We calculated that the average cost to treat a child with BL was 
US$12829, which is considerably lower than the reported $40400 it cost to treat paediatric 
cancer in a high income country like USA (25) and somewhat lower than the treatment of 
ALL in a middle income country (Brazil $16 700(29)).  The cost correlated well to a 
previous South African study that calculated the average cost to treat a child with 
Hodgkin's Lymphoma at $6647(28), when considering that the cost of hospitalisation 
which contributed nearly half of the cost in the treatment of BL, was excluded in that study. 
As expected, the cost to treat BL was much higher than the cost of treating infectious 
diseases such as tuberculosis or pneumonia.(32,33,36) These studies unfortunately were 
not cost-effective analyses, so the cost-effectiveness could not be compared. The paucity 
of cost-effectiveness studies in middle-income countries makes it difficult to compare the 
cost-effectiveness of BL to other infectious diseases. 
6.3 Advanced stages of disease 
As expected, this limited study also confirmed the poor prognosis associated with 
advanced disease (Group C).(14),(15) 
We found a trend that the treatment of advanced stage disease (Group B and C) was 
more expensive, per patient, than early stage disease (Group A). This was in spite of 
some children with more advanced stages demising very soon after presentation to 
hospital, thus incurring very low cost. The US$ to avert 1 DALY to GDP per capita ratio for 
the different disease groups were 0.03:1, 0.09:1, and 0.6:1 for respectively Groups A, B 
and C. Two children included in this study (one Group B and one Group C), required the 
use of significantly more resources, e.g. blood product transfusions, admission to the 
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intensive care unit, special investigations and procedures than the other children who 
survived. The cost of chemotherapy administered to the child with Group C disease was 
also the second highest in the cohort. This had a strong influence on the above results. 
As other studies did not differentiate between the different stages of presentation, it is not 
possible to validate this trend with the literature. 
6.4 Burkitt Lymphoma and HIV infection 
In this small cohort, there was no evidence that HIV comorbidity was associated with a 
worse prognosis. This was unexpected as the literature suggests otherwise.(14),(15)  
 A trend was seen for the treatment of HIV positive patients to cost more than HIV negative 
patients, but was still well within the threshold of very cost-effectiveness. The total US$  
required to avert 1 DALY per GDP per capita ratio for HIV infected children with Burkitt 
Lymphoma was 0.11:1 versus 0.09:1 in HIV uninfected children. We found no other 
studies that compared the cost or cost-effectiveness of treating HIV-infected paediatric 
cancer patients to HIV-uninfected paediatric cancer patients. 
This novel pilot data may be used when health care workers in developing countries need 
to lobby for equal cancer treatment for patients with HIV disease. When the HIV pandemic 
was young, many doctors believed that affected patients should not receive cancer 
treatment. This view started to change once ARTs became successful and available and 
cancer patients with HIV started to survive, but in some developing countries, this belief 
may persist. 
6.5 Cost breakdown 
Cost related to general supportive care was the largest proportion of the cost.  This was 
somewhat surprising considering the expensive procedures, investigations and medication 
used. On the other hand, the chemotherapy agents used in the BL LMB protocol, are 
drugs that have been used for many decades and are therefore not that expensive, bar the 
anthracyclines (TBH pharmacy price list). Rituximab, an expensive monoclonal antibody 
used in the treatment of adult BL, is not used in this protocol either. 
Hospitalisation and laboratory tests made up the bulk of the cost of supportive care. Full 
blood counts and electrolyte measurements were the most costly tests, mainly because of 
the frequency of repetition.  This may be against a general perception that more 
specialized investigations, expensive chemotherapy and invasive procedures would drive 
the cost.  
The second largest component of costs consisted of blood products administered, even 
though a restrictive blood transfusion policy was utilised in the unit. Severe bone marrow 
suppression is both disease- related and a treatment- related complication.(10) The use of 
leukocyte-depleted products (mainly to reduce the risk of allo-immune transfusion 
reactions) further contributed to this cost. In a Norwegian cost analysis in Hodgkin's 
Disease, hospital stay was found to be the main contributor to costs (36% of total cost), 
which correlates well with the findings of this study.(27) 
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6.6 Weaknesses and strengths 
The first major limitation of the study is the small sample size that was studied.  This 
prevented the calculation of statistical significance or confidence intervals.  Being a 
retrospective study, it was dependent on good record keeping practices, thus there may 
also have been inaccurate or missing data 
The third is the fact that the study only included one treatment centre.  To some extent, 
however, these factors were negated by the fact that the characteristics of this cohort 
compared very well to that represented in the literature. The patients were also managed 
at a central academic health care facility using a standardised treatment protocol that is 
currently used in all the paediatric oncology units (POUs) in South Africa.  
A strength would therefore be that the cost of treating patients with BL at other public 
sector POUs in South Africa should be very similar. The diagnostic investigations and 
supportive care required for treating patients with BL are available at all the units and the 
cost of the various contributing factors would be similar, since the overwhelming majority 
of units are in the public sector and therefore prices are similarly regulated. The exception 
would be that not all units have access to a paediatric intensive care unit.  
The cost of treating a patient with BL in the private sector will most likely be higher, due to 
a different tariff structure; therefor our findings may not be applicable to the private sector 
and requires further research.  
6.7 Relevance and implications  
The main finding of the study is that it is very cost-effective to treat children with BL, even 
though it costs much more than treating children with potentially life threatening infectious 
diseases.  The main factor contributing to the cost-effectiveness is the 100% mortality rate 
of untreated BL, compared to treatment, which has a reasonable chance of permanent 
cure in patients with a long life ahead of them.  The large margin by which cost-
effectiveness was achieved in this representative sample would suggest: 
- That the treatment of any paediatric cancer with a chance of lasting cure is likely to be 
cost effective, even if patients present with late stage disease or HIV infection. 
- In economic strife, public funding should not be diverted away from the treatment of 
paediatric cancer towards treatment of infectious diseases, even though the latter is a 
more common cause of death in South Africa.  
- This study, or similar studies in future, could be used by advocates for treatment of 
children with cancer in middle-income countries. 
- Any intervention that would improve the cure rate would further improve cost-
effectiveness, even if the intervention were expensive.  
- To improve cost-effectiveness even further, critical evaluation of the need of hospital 
admission days, careful consideration when requesting routine blood investigations, 
prevention of infectious complications and strict reinforcement of a restrictive blood 
transfusion policy should be targeted.  
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6.8 Recommendation for future studies 
The findings should be validated by repeating the study in another treatment centre, or in a 
private sector treatment centre.  A similar study in a different type of paediatric cancer 
would also serve as verification.  It would also be interesting to see if the treatment of 
paediatric cancer would still be cost-effective if the study design were repeated in a low-
income country. 
6.9 Final conclusion 
The treatment of children with Burkitt Lymphoma in Tygerberg Children’s Hospital, South 
Africa is very cost effective, as it is well below the WHO-CHOICE threshold of very cost-
effectiveness. It is also very cost-effective to treat children with Burkitt Lymphoma who 
present with advanced disease, as well as children with associated HIV infection.  
Cost constraints should therefore not be a limitation to treating children with Burkitt 
Lymphoma, even if they present with advanced stage disease or HIV infection. 
Similar cost-effective studies in another type of paediatric cancer, private health sector or 
low-income countries, should be performed to verify this data. 
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Appendix 1 
Research protocol for the Committee for Human Research 
Project: 
The cost effectiveness of treating paediatric cancer in South Africa –  
A review of treatment cost for Burkitt lymphoma 
Protocol Summary: 
This will be a retrospective cost-effectiveness analysis of children diagnosed with Burkitt 
lymphoma at Tygerberg Children’s Hospital from 2005-2010.  The objective of the analysis 
will be to determine the true cost of management and determining the cost-effectiveness. 
Childhood cancers are rare and require resource-intensive medical services to cure. 
Critical evaluation of the costs of management is scarce and there is a need to estimate if 
treatment of childhood cancers in South Africa meets the threshold of cost-effectiveness. 
Cost effectiveness is defined as the ratio of monetary expense required to avert 1 
Disability Adjusted Life Year (DALY) to the annual gross domestic product (GDP) per 
capita in South Africa. 
The purpose of the study is to review information obtained from all the children diagnosed 
and treated with Burkitt lymphoma(BL) at the Oncology Unit of Tygerberg Children’s 
Hospital, from 2005-2010. The emphasis of the study will be to determine the average cost 
of treatment of children with Burkitt Lymphoma and to extrapolate its cost effectiveness.  
 
Literature review: 
Although cancer in children is rare, it is still the second highest cause of mortality in 
children in High income, Western countries.  However, it is not even in the top 10 causes 
of death in middle and Low income African countries (1). Burkitt lymphoma, endemic to 
equatorial Africa (2), comprises 30 - 50% of paediatric cancers in these countries (3, 4).   
In South-Africa, the incidence rate of BL in children (<15 years), is approximately 0.1 per 
100000 per year (5).  However, it is still one of the most common paediatric cancers in 
South Africa, comprising roughly 40% of lymphomas, which is ranked second most 
common cancer, behind leukemia (1, 5, and 6).  Although there is a known association 
between HIV and Burkitt’s lymphoma, the high prevalence of HIV has only caused a 
gradual rise in the incidence of paediatric BL in Africa(2,7), possibly  attributable to the 
poor survival of African children born with HIV. 
Burkitt’s lymphoma is an aggressive form of B-cell; non-Hodgkin’s Lymphoma (NHL) and 
divided by the WHO into 3 different clinical variants:  endemic, sporadic and 
immunodeficiency associated.  
- Endemic: Occurs in children from equatorial Africa and is highly associated with 
Epstein-Barr Virus (EBV).  South Africa is not an endemic country. 
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- Sporadic: Accounts for 40-50% of childhood NHL.  
- Immunodeficiency-associated:  Occurs in patients infected with HIV, or other causes of 
immunosuppression (primary immunodeficiency, chronic immunosuppressive therapy, 
etc.). (8) 
BL is a rapid growing tumor, that usually present primarily in the abdomen or head-and-
neck(7,8) with a peak incidence in children aged 6-8 years and affects boys more common 
than girls(4,5,7). St Jude system for Non-Hodgkin’s Lymphoma is used to stage BL.  At 
diagnosis, most patients (60-70%) present with stage 3 diseases (4, 7).  Untreated, BL 
leads to a 100% mortality rate, usually within 4-6 months (20). The long term cure rate for 
BL varies from <35% in Africa, using single or low dose chemotherapy agents and up to 
90% in the first world setting, using high dose chemotherapy and providing optimal 
supportive care(4),.  In SA, where the LMB=96 protocol is widely used, a recent 
retrospective study found a 77% cure rate in HIV negative patients.  Once a 5 year survival 
is reached, BL has an extremely low relapse rate (17).  
The LMB 96 treatment regime groups patients into 3 categories: 
Group A comprises of Stage I and abdominal Stage II disease that is completely 
resectable.  After resection this group receives two cycles of chemotherapy (COPAD). 
Group B consists of patients with non-resectable disease in any stage, but with no central 
nervous system (CNS) involvement and less than 25% bone marrow (BM) involvement.  
These patients receive an initial cycle (COP), followed by 2 induction cycles (COPADM) 
and 2 consolidation cycles (CYM), but would be transferred to group C if they still have 
residual disease after the first consolidation cycle. 
Group C consists of patients with CNS disease and/or BM involvement of greater than 
25%.  They receive initiation and induction cycles as above, with consolidation cycles 
(CYVE) and 4 maintenance cycles.  Patients with CNS involvement also receive intra-
thecal therapy as well as added Methotrexate between consolidation treatments. Over the 
last 10 years minimal changes have been made to the standardised protocol of managing 
children with Burkitt Lymphoma at Tygerberg Hospital. 
 Common complications during treatment include mucositis, infections, cytopenias, 
electrolyte disturbances and tumor lysis syndrome (22, 23).  
 
As expected, HIV co-infection has been shown to have a significantly negative impact on 
survival, even though the objective tumour response to treatment appears similar (7, 13).  
 Life expectancy in South-Africa is 59.58 years (males 57, females 61)(14).  As BL is an 
AIDS defining disease, the life expectancy for the HIV positive patients would be much 
poorer, even in the event of successful treatment and HAART initiation. During the last few 
years, due to advances in ARV therapy and early initiation of ARV’s in all children under 
the age of 5 years, the life expectancy of HIV infected children are improving. In the USA, 
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the mean age at death for HIV-infected children improved from 8.9 years in 1994 to 18.2 
years in 2006. 
 The Global Burden of Disease working group has set the Disability Weight for Non-
Hodgkin’s Lymphoma at 0.09(16).  The South African Gross Domestic Product (GDP) per 
capita is $11600(18). 
The treatment of Burkitt  Lymphoma has been shown to be cost effective in Malawi(15), 
applying the WHO guide to cost effective analysis, but did not take HIV co-infection in 
account and to my knowledge, no such study has been done in South-Africa.   
 
Study Question: 
Does the cost of treating Burkitt lymphoma at Tygerberg Children’s Hospital meet the 
calculated threshold of cost-effectiveness? This is defined as three times the South 
Africa’s annual gross domestic product (GDP) per capita. 
 
Research Question: 
What is the monetary expense required to avert 1 Disability adjusted Life Year (DALY) of 
children with Burkitt lymphoma? 
 
Aim, Objective and Impact: 
This study will be a retrospective audit using the Tygerberg Children’s Hospital tumour 
registry from 2005 to 2010 and selected patient’s financial records. 
The purpose of the study will be to review the data collected at Tygerberg Children’s 
Hospital and then to document the incidence of Burkitt lymphoma, the age of presentation, 
race, gender, stage of presentation, amount of hospital admission days, chemotherapy, 
radiotherapy, surgery, outcome to date and associated costs of treatment. 
The study will include the following information: 
 Race; Gender 
 Age at diagnosis 
 Stage at diagnosis 
 Number of days admitted to hospital. Number of outpatient appointments 
 Complications 
 Adjunctive treatment 
 Chemotherapy; Radiotherapy; Surgery 
 Outcome (Proportion of children who recover) 
 Financial statements (where applicable) 
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Methodology 
Study Design: A retrospective, descriptive study. 
Inclusion criteria: All children diagnosed with Burkitt lymphoma at the Tygerberg Paediatric 
Oncology Unit from 2005 – 2010. 
Data collection: Data will be obtained from the tumour registry of Tygerberg Children’s 
Hospital, National Health Laboratory System (NHLS) data and Tygerberg Hospital 
department of finances. 
Data will include: Race, age, gender, age at diagnosis, stage at diagnosis, treatment 
received, duration of hospital admissions, chemotherapy, radiotherapy, surgery, outcome 
to date and associated monetary expenses of treatment. Only direct medical costs 
associated with treating Burkitt’s lymphoma will be used, which includes: costs of 
investigations; costs of hospital admissions during treatment period, costs of 
chemotherapy drugs and costs of follow-up care. Direct non-medical costs will not be 
included (transport costs, etc.) and neither would costs associated with loss of productivity 
of parents (due to illness of the children). 
Program costs: Costs of central administration of intervention (planning and management 
of health system) and costs of developing interventions (training costs to achieve 
skills required to deliver intervention) will not be included in this research. 
Cost data: Data of related direct healthcare costs of investigations and treatment for 
Burkitt’s lymphoma will be obtained from Tygerberg Hospital’s pharmacy, radiology and 
pathology departments, at 2010 tariffs. Overhead costs: Personnel costs and proportion of 
time they devote to managing patient and building costs (and proportion of space used) 
will also be included in calculations. 
Costs of unrelated illnesses treated during admission period will not be included and 
neither will future costs arising in years of life gained, as this is beyond the scope of this 
research. Costs will be calculated in South African Rand (ZAR) and converted to US Dollar 
(USD) at an appropriate exchange rate (PPP rate). Costs will be adjusted for inflation 
using appropriate consumer price index (CPI), using 2010 as the base year. 
Health outcomes: If information from the literature regarding disability weight and average 
duration of disability of Burkitt’s lymphoma specific to South Africa is available, the total 
number of disability-adjusted life years (DALYs) due to Burkitt’s lymphoma will be 
calculated. Using standard methods from the WHO Global Burden of Disease working 
group, the total number of DALY’s due to Burkitt’s Lymphoma are calculated by adding the 
years of life lost (YLL) due to ill health, disability or early death, with the years lived with 
disability (YLD). Years of life lost (YLL) without treatment is calculated by subtracting the 
estimated age at death without treatment from the standard life expectancy in South 
Africa, multiplied by the absolute annual number of cases of Burkitt’s lymphoma. Years 
lived with disability (YLD) is calculated by multiplying the estimated duration of illness with 
and without treatment by the disability weight for Burkitt ’s lymphoma (as set by the Global 
burden of Disease working group) and the incident number of cases. 
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Using the WHO-CHOICE framework for generalised cost-effectiveness to estimate the 
cost effectiveness of treating Burkitt lymphoma in South Africa. Cost-effectiveness is 
defined as the ratio of the monetary expense required to avert 1 DALY to the annual gross 
domestic product (GDP) per capita of South Africa. A ratio of 3:1 is considered cost 
effective and a ratio of 1:1 is considered very cost-effective. Thus if the cost to avert 1 Daly 
is equal or less than $34800 it is cost-effective to treat Burkitt Lymphoma and if it is 
$11600 or less it is regarded as very cost-effective. 
 
Ethical points: 
The project will be registered with the Health Research Ethics Committee of Stellenbosch, 
prior to collection of data.  The principal investigator will collect all the relevant information 
from the file and complete a coded data sheet. The data will be collected anonymously 
using a study code; no patient identifying data will be used on the data-capturing sheet. 
Only the primary investigator will retain the patient identification log, as a separate 
document, in a secure location. This audit will not deviate from standard clinical practice.   
Consent to pursue with the research will be obtained from the Superintendent of 
Tygerberg Children’s’ Hospital to access data mentioned above. I would like to request a 
waiver from obtaining individual informed consent.  
 
Statistical analysis 
Cost of treatment will be expressed in South African Rand and converted to US Dollars at 
the current exchange rate at the time of analysis. Mean cost of treatment per patient will 
be calculated. Confidence intervals will be calculated where applicable.  A Statistician will 
oversee data analysis to ensure correct statistical methods. 
 
Budget 
All administrative costs will be carried by the principal investigator.  
 
Time plan and logistics 
Collection, evaluation and analysis of data will be performed by Dr C Kay.                                 
Data will then be available to a statistician for statistical analysis.                                                     
Professional advice regarding health economical practises and evaluations will be 
obtained by a health economist. The project will be overseen by Prof C Stefan. 
Time goals:                                                                                                                                                         
- Research protocol formulated:  2013    
-Presentation to the postgraduate committee 
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- Submission to Ethics Committee and Chief Director, Tygerberg Hospital,  for approval to      
perform research and access patient data: October 2013                                                                                                                                                
- Collection of data completed:  March 2014                                                                                             
- Data analysis: June 2014                                                                                                                              




 Calculate the true cost of treating a patient with Burkitt lymphoma, in South Africa. 




Assess the perception that the management of paediatric cancer is a resource depleting 
financial burden. 
Increase awareness of the need for economic evaluations and importance of cost effective 
management. 
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Appendix 3  
UPFS RADIOLOGY CODE BOOK 
 
   Ana  P  I 
 
  X-ray skeletal survey under five years (00110)   B 
  X-ray skeletal survey over five years (00115)   B 
   X-ray sinogram any region (00120)    B 
   X-ray with mobile unit in other facility (00130)    A 
  X-ray control view in theatre any region (00135)   A  
   X-ray fluoroscopy any region (00140)    A 
   X-ray fluoroscopy guidance for biopsy, any region (00145)    B 
   X-ray C-Arm (equipment fee only, not procedure) per half hour (00150)    A 
   X-ray C-arm fluoroscopy in theatre per half hour (procedure only) (00155)    A 
   X-ray fixed theatre installation (equipment fee only) (00160)    A 
   X-ray examination contrast material (00190)   Vary 
   Ultrasound with mobile unit in other facility (00210)     A 
   Ultrasound intra-operative study (00220) A   B 
   Ultrasound guidance (00230)    C 
   Ultrasound guidance for tissue ablation (00240)    C 
   Ultrasound limited Doppler study any region (00250)    B 
   CT planning study for radiotherapy (00310)    D 
   CT guidance (separate procedure) (00320)    C 
   CT guidance, with diagnostic procedure (00330)    C 
   CT guidance and monitoring for tissue ablation (00340)    D  
   CT examination contrast material (00390)    Vary 
   MR study of the whole body for metastases screening 
(00410) B     E  
   MR Spectroscopy any region (00420)                                                                                                                                           
 B     D  
   MR guidance for needle replacement (00430) B  D 
  MR low field strength imaging of peripheral joint any region (00440)                          B   B  
   MR planning study for radiotherapy or surgical procedure (00450)     D 
   MR planning study for radiotherapy or surgical procedure, with contrast (00455)    D 
   Analogue monoplane screening table (00510)    D 
   Analogue monoplane table with DSA attachment (00520)    D 
   Dedicated angiography suite: Analogue monoplane unit. Once off charge per patient by owner of equipment (00530)    D 
   Digital monoplane screening table (00540)    E 
   Dedicated angiography suite: Digital monoplane unit. Once off charge per patient by owner of equipment (00550)    E 
   Dedicated angiography suite: Digital bi-plane unit. Once off charge per patient by owner of equipment (00560)    E 
   Angiography and interventional examination contrast material (00590)    Vary 
 
 Skull and Brain 
   X-ray of the skull (10100)    A 
   X-ray tomography of the skull (10110)    B 
   X-ray shuntogram for VP shunt (10120)    C 
   Ultrasound of the brain – Neonatal (10200) A    B 
   Ultrasound of the brain including Doppler (10210)    C 
   Ultrasound of the intracranial vasculature, including B mode, pulse and colour Doppler (10220)    C 
   CT Brain uncontrasted (10300) B   D 
   CT Brain with contrast only (10310)  B    D 
   CT Brain pre and post contrast (10320)  B   D 
   CT brain pre and post contrast for perfusion studies (10325)                                         B                   D 
  CT angiography of the brain (10330)                                                                                                                              B  E 
   CT of the brain pre and post contrast with angiography (10335)                                                                                        B   E 
   CT brain for cranio-stenosis including 3D (10340)                                                                                                      B   D 
   CT Brain stereotactic localization (10350)                                                                                                                                       B   C 
   CT base of skull coronal high resolution study for CSF leak (10360)                                                                                              B   D 
   MR of the brain, limited study (10400)                                                                                                                                             B   D 
   MR of the brain uncontrasted (10410) B   E 
   MR of the brain with contrast (10420) B   E 
   MR of the brain pre and post contrast (10430) B   E 
   MR of the brain pre and post contrast, for perfusion studies (10440) B   E 
   MR of the brain plus angiography (10450) B   E 
   MR of the brain pre and post contrast plus angiography (10460) B   E 
   MR angiography of the brain uncontrasted (10470) B   E 
   MR angiography of the brain contrasted (10480) B   E 
   MR of the brain, with diffusion studies(10485) B   E 
   MR of the brain, pre and post contrast, with diffusion studies, (10490) B   E 
   MR study of the brain plus angiography plus diffusion, uncontrasted (10492) B   E 
   MR of the brain pre and post contrast plus angiography and diffusion (10495) B   E 
   Arteriography of intracranial vessels: 1 - 2 vessels (10500) B   D 
   Arteriography of intracranial vessels: 3 - 4 vessels (10510) B   E 
   Arteriography of extra-cranial (non-cervical) vessels (10520) B   D 
   Arteriography of intracranial and extra-cranial (non-cervical) vessels (10530) B   E 
   Arteriography of intracranial vessels (4) plus 3 D rotational angiography (10540) B   E 
   Arteriography of intracranial vessels (1) plus 3D rotational angiography (10550) B   D 
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 Facial bones and nasal bones 
   X-ray of the facial bones (11100)    A 
   X-ray tomography of the facial bones (11110)    B 
   X-ray of the nasal bones (11120)    A 
   CT of the facial bones (11300) B   D 
  CT of the facial bones with 3D reconstructions (11310) B   D 
   CT of the facial bones/soft tissue, pre and post contrast (11320) B   D 
   MR of the facial soft tissue (11400) B   E 
   MR of the facial soft tissue pre and post contrast (11410) B   E 
   MR of the facial soft tissue plus angiography, with contrast (11420) B   E 
  MR angiography of the facial soft tissue (11430) B  E 
 Orbits, lacrimal glands and tear ducts    
   X-ray orbits less than three views (12100)    A 
   X-ray of the orbits, three or more views, including foramina (12110)        B 
   X-ray of the orbits for foreign body (12120)    A 
   X-ray tomography of the orbits (12130)    B 
   X-ray dacrocystography (12140) B   A 
    Ultrasound of the orbit/eye (12200)          B  
   Ultrasound of the orbit/eye including Doppler (12210)    C  
   CT of the orbits single plane (12300) B   C 
   CT of the orbits, more than one plane (12310) B   D 
   CT of the orbits pre and post contrast single plane (12320) B   D 
   CT of the orbits pre and post contrast multiple planes (12330) B   D 
   MR of the orbits (12400) B   E 
   MR of the orbitae, pre and post contrast (12410) B   E 
 Paranasal sinuses  
      X-ray of the paranasal sinuses, single view (13100)               A 
       X-ray of the 
paranasal sinuses, two or more views (13110)    A   
        X-ray 
tomography of the paranasal sinuses (13120)    B 
    X-ray of the naso-pharyngeal soft tissue (13130)    A 
    CT of the paranasal sinuses single plane, limited study (13300) B   B 
    CT of the paranasal sinuses, two planes, limited study (13310) B   C 
    CT of the paranasal sinuses, any plane, complete study (13320) B   C 
    CT of the paranasal sinuses, more than one plane, complete study (13330) B   D 
    CT of the paranasal sinuses, any plane, complete study: pre and post contrast (13340) B   D 
    CT of the paranasal sinuses, more than one plane, complete study; pre and post contrast (13350) B   D 
    MR of the paranasal sinuses (13400) B   E 
  MR of the paranasal sinuses, pre and post contrast (13410) B  E 
  Mandible, teeth and maxilla 
    X-ray of the mandible(14100)    A 
    X-ray orthopantomogram of the jaws and teeth (14110)    A  
    X-ray maxillofacial cephalometry (14120) A   A 
    X-ray of the teeth single quadrant (14130)    A 
    X-ray of the teeth more than one quadran (14140)    A 
    X-ray of the teeth full mouth (14150)    A 
    X-ray tomography of the teeth per side (14160)    A 
    CT of the mandible (14300)    D 
    CT of the mandible, pre and post contrast (14310)    D 
    CT mandible with 3D reconstructions (14320)    D  
    CT for dental implants in the mandible (14330)    D  
    CT for dental implants in the maxilla (14340)    D 
    MR of the mandible/maxilla (14400) B   E 
  MR of the mandible/maxilla, pre and post contrast (14410) B   E   
  
           TM Joints 
    X-ray tempero-mandibular joint, left (15100)                                                                                                                             A     
    X-ray tempero-mandibular joint, right (15110)     A 
   X-ray tomography tempero-mandibular joint, left (15120)    A 
     X-ray tomography tempero-mandibular joint, right (15130)          A 
    X-ray arthrography of the tempero-mandibular joint, left (15140) A    A  
    X-ray arthrography of the tempero-mandibular joint, right (15150) A    A 
    Ultrasound tempero-mandibular joints, one or both sides (15200) A    B 
    CT of the tempero-mandibular joints (15300) B    D 
    CT of the tempero-mandibular joints plus 3D reconstructions (15310) B    D 
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    CT arthrogram of the tempero-mandibular joints (15320) B    D 
    MR of the tempero-mandibular joints (15400) B    E 
    MR of the tempero-mandibular joints, pre and post contrast (15410) B    E 
    MR arthrogram of the tempero-mandibular joints (15420) B    E  
   Mastoids and internal auditory canal 
    X-ray of the mastoids, unilateral(16100)    A 
    X-ray of the mastoids, bilateral(16110)    B 
    X-ray tomography of the petro-temporal bone, unilaterall (16120)    A 
    X-ray tomography of the petro-temporal bone, bilateral (16130)    A 
    X-ray internal auditory canal, bilateral (16140)    B 
       X-ray tomography of the internal auditory canal, bilateral (16150)           B 
        CT of the mastoids 
(16300) B   B       
   CT of the internal auditory canal (16310) B   D 
   CT of the internal auditory canal, pre and post contrast (16320) B    D 
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   CT of the middle and inner ear structures, high definition including all reconstructions in various planes (16340) B    D 
   MR of the internal auditory canals, limited study (16400) B    D 
   MR of the internal auditory canals, pre and post contrast, limited study (16410) B    E  
  MR of the internal auditory canals, pre and post contrast, complete study (16420) B  E 
  
  MR of the ear structures (16430) B   E 
      MR of the ear structures, pre and post contrast (16440) B    E 
  
 Sella turcica 
   X-ray of the sella turcica (17100)    A 
   X-ray tomography of the sella turcica (17110)    B 
   CT of the sella turcica/hypophysis (17300) B    C 
   CT of the sella turcica/hypophysis, pre and post contrast (17310) B    D 
     MR of the hypophysis 
(17400) B    D 
       MR of the hypophysis, pre and post contrast (17410) B   E  
    Salivary glands and floor of the mouth 
                       X-ray of the salivary glands and ducts for calculus (18100)                                                                                                                                    A 
    X-ray of the salivary glands and ducts for calculus (18110)          A  
  X-ray sialography, per gland (18120)        A 
    Ultrasound of the salivary glands/floor of the mouth (18200)    B 
       CT of the salivary glands, uncontrasted (18300) B        C 
      CT of the salivary glands/floor of the mouth, pre and post contrast (18310) B   D 
                       CT sialography (18320)                                                                                     B     D    
             MR of the 
salivary glands/floor of the mouth (18400) B    E 
    MR of the salivary glands/floor of the mouth, pre and post contrast (18410) B    E 
                Neck 
    X-ray of soft tissue of the neck (20100)    A 
    X-ray of the larynx including tomography (20110)    A 
      X-ray laryngography (20120)          A 
          X-ray evaluation of 
pharyngeal movement and speech by screening and / or cine with or without video recording (20130)         C 
    Ultrasound of the thyroid (20200)    B 
    Ultrasound of soft tissue of the neck (20210)    B 
    Ultrasound of the carotid arteries, bilateral including B mode, pulsed and colour Dopple r(20220) B   B 
      Ultrasound of the entire extracranial vascular tree including carotids, vertebral and subclavian vessels with B mode,                   B    D 
      pulse and colour Doppler (20230)  
  Ultrasound study of the venous system of the neck including pulse and colour Doppler (20240)    B  B 
                      CT of the soft tissues of the neck (20300) B   C 
                     CT of the soft tissues of the neck, with contrast (20310) B   D 
       CT of the soft tissues of the neck, pre and post contrast (20320) B   D 
      CT angiography of the extracranial vessels in the neck (20330) B   E 
      CT angiography of the extracranial vessels in the neck and intracranial vessels of the brain (20340) B   E 
               CT angiography 
of the extracranial vessels in the neck and intracranial vessels of the brain B   E 
         plus a pre and 
post contrast study of the brain (20350) 
       MR of the soft tissue of the neck (20400) B   E 
      MR of the soft tissue of the neck, pre and post contrast (20410) B   E 
      MR of the soft tissue of the neck and uncontrasted angiography (20420) B   E      
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         MR angiography of the extracranial vessels in the neck, without contrast (20430) B   E 
         MR angiography of the extracranial vessels in the neck, with contrast (20440) B   E 
        MR angiography of the 
extra and intracranial vessels with contrast (20450) B   E      
       MR angiography of the intra and extra cranial vessels plus brain, without contrast (20460) B   E 
        MR angiography of the 
intra and extra cranial vessels plus brain, with contrast (20470) B   E 
    Arteriography of cervical vessels: carotid 1 - 2 vessels (20500) B   D 
     Arteriography of cervical 
vessels: vertebral 1 - 2 vessels (20510) B   D 
    Arteriography of cervical vessels: carotid and vertebral (20520) B   E 
        Arteriography of aortic arch and cervical vessels (20530) B   E 
       Arteriography of aortic arch, cervical and intracranial vessels (20540) B  E 
  Venography of jugular and vertebral veins (20550) B  D 
  
 Thorax  
   Chest wall, pleura, lungs and mediastinum 
      X-ray of the chest, single view (30100)          A 
              X-ray of the 
chest two views, PA and lateral (30110)    B 
   X-ray of the chest complete with additional views (30120)    B 
   X-ray of the chest complete including fluoroscopy (30130)    B 
   X-ray tomography of the chest (30140)    B 
   X-ray of the ribs (30150)    A 
   X-ray of the chest and ribs (30155)    B 
   X-ray of the thoracic inlet (30160)    A 
   X-ray of the sterno-clavicular joints (30170)    A 
   X-ray tomography of the sterno-clavicular joint (30175)    B 
   X-ray of the sternum (30180)    A 
   X-ray tomography of the sternum (30185)    B 
   Ultrasound of the chest wall, any region (30200)    B 
   Ultrasound of the pleural space (30210)    B 
   Ultrasound of the mediastinal structures (30220)    B 







   Ana  P  I 
 
   CT of the chest uncontrasted (30310) B   D 
   CT of the chest contrasted (30320) B   D  
   CT of the chest, pre and post contrast (30330) B   D 
   CT of the chest, limited high resolution study (30340) B   B 
  
      CT of the chest, complete high resolution study (30350) B   D 
         CT of the chest, 
complete high resolution study with additonal prone and expiratory studies (30355) B   D 
        CT of the chest for pulmonary embolism (30360) B   E 
          CT of the chest 
for pulmonary embolism with CT venography of abdomen, pelvis and lower limbs (30370) B   E 
  
           MR of the chest (30400) B   E 
        MR of the chest with uncontrasted angiography (30410) B   E 
      MR of the chest, pre and post contrast (30420) B   E 
   Oesophagus 
      X-ray barium swallow (31100) A   B  
    Xray 3 phase dynamic contrasted swallow (31105) B   C 
        X-ray barium 
swallow, double contrast (31110) B   C 
                  X-ray barium 
swallow with cinematography (31120)  B   C 
 Aorta and large vessels 
      Ultrasound intravascular arterial or venous assessment for intervention, once per  B   B  
    complete procedure (32200)            
      Ultrasound intravascular (IVUS) first vessel (32210) B   B  
      Ultrasound intravascular (IVUS) subsequent vessels (32220) B   B  
      CT angiography of the aorta and branches (32300)  B   E 
                      CT 
angiography of the thoracic and abdominal aorta and branches (32305) B   E 
        CT angiography of the pulmonary vasculature (32310) B   E 
           MR angiography of the 
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aorta and branches (32400) B   E     
        MR angiography of the pulmonary vasculature (32410) B   E 
      Arteriography of thoracic aorta (32500) B    D 
      Arteriography of bronchial intercostal vessels alone (32510) B   D 
      Arteriography of thoracic aorta, bronchial and intercostal vessels (32520) B   E 
      Arteriography of pulmonary vessels (32530) B     E 
      Arteriography of heart chambers, coronary arteries (32540) B    D 
      Venography of thoracic vena cava (32550) A   D 
      Venography of vena cava, azygos system (32560) A     E 
      Venography patency of A-port or other central line (32570) A   C 
   Heart  
     Ultrasound study of the heart for foetal or paediatric cases including Doppler (33205) B   C 
     Ultrasound study of the heart, including Doppler (33200)        B 
               Ultrasound study of the heart trans-oesophageal (33210)                                                                                        B 
    Ultrasound intravascular imaging to guide placement of intracoronary stent once per vessel (33220) B   B 
        CT 
anatomical/functional study of the heart (33300) B   D 
      CT angiography of heart vessels (33310) B   E 
   MR of the heart, anatomical study (33400) B    E 
   MR of the heart, anatomical and functional study (33410) B    E 
   MR of the heart, pre and post contrast (33420) B    E 
   MR angiography of the heart vessels (33430) B    E 
   MR of the heart, anatomical, functional and coronary angiography (33440) B    E  
   Mamma 
   X-ray mammography including ultrasound (34100)    B 
   X-Ray mammography unilateral, including ultrasound (34101)    B 
   X-ray mammography galactography (34105)    C 
   X-ray mammography study for localization (34110)    B 
   X-ray stereotactic mammography – localization (34120)    C 
   X-ray stereotactic mammography – biopsy (34130) B    B 
   X-ray of biopsy specimen of the mamma (34140)    A 
   X-ray Mammotome hand held biopsy apparatus (34150)    C 
   Ultrasound study of the breast (34200)    B 
   Ultrasound guided aspiration FNA/localisation of the breast (34205) B    B 
   Computer assisted diagnosis for mammography (34300)    A 
   MR study of the breast (34400) B    E 
   MR study of the breast pre and post contrast (34410) B    E   
 
               Abdomen and Pelvis 
               Abdomen/stomach/bowel 
   X-ray of the abdomen (40100)     A 
   X-ray of the abdomen supine and erect, or decubitus (40105)    B 
   X-ray of the abdomen multiple views including chest (40110)    C 
   X-ray tomography of the abdomen (40120)    B 
   X-ray barium meal single contrast (40140)    B 
   X-ray barium meal double contrast (40143)    C 
   X-ray barium meal double contrast with follow through (40147)    C 
   X-ray small bowel enteroclysis (meal) (40150)    B 
   X-ray small bowel meal follow through single contrast (40153)    C 
   X-ray small bowel meal with pneumocolon (40157)    D 
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   X-ray large bowel enema single contrast (40160)    B 
   X-ray large bowel enema double contrast (40165)    C 
   X-ray guided gastro oesophageal intubation (40170)    A 
  
   X-ray guided duodenal intubation (40175)    A 
  X-ray defaecogram (40180)                                                                                                                                                                                     B  
   X-ray guided reduction of intussusception (40190)                                                                                                                                                  B  
   Ultrasound study of the abdominal wall (40200)                                                                                                                                                     B 
   Ultrasound study of the whole abdomen including the pelvis (40210)     B 
  CT study of the abdomen (40300) B  D 
  
   CT study of the abdomen with contrast (40310) B    D 
   CT study of the abdomen pre and post contrast (40313) B    D 
   CT of the pelvis (40320) B    D 
   CT of the pelvis with contrast (40323)                                                                                      B         D  
   CT of the pelvis pre and post contrast (40327)                                                                                                                          B       D  
  CT of the abdomen and pelvis (40330)                                                                                                                                         B    D  
   CT of the abdomen and pelvis with contrast (40333)                                                                                                                       B       D  
   CT of the abdomen and pelvis pre and post contrast (40337)                                                             B       D  
   CT triphasic study of the liver, abdomen and pelvis pre and post contrast (40340) B    D  
  CT of the chest, abdomen and pelvis without contrast (40345) B   D 
   CT of the chest, abdomen and pelvis with contrast (40350) B    D 
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   CT of the chest triphasic of the liver, abdomen and pelvis with contrast (40355)  B    E 
   CT of the base of skull to symphysis pubis with contrast (40360)   B    E 
   CT colonoscopy (40365)  B    D 
   MR of the abdomen (40400)  B    E 
   MR of the abdomen pre and post contrast (40410)  B    E 
   MR of the pelvis, soft tissue (40420)  B    E 
   MR of the pelvis, soft tissue, pre and post contrast (40430)   B               E  
               Liver, spleen, gall bladder and pancreas 
    X-ray ERCP including screening (41100) B   B 
   X-ray cholangiography intra-operative (41110)) B   B 
   X-ray T-tube cholangiography post operative (41120) B   B 
   X-ray transhepatic percutaneous cholangiography (41130) B   B 
   Ultrasound study of the upper abdomen (41200)    B 
   Ultrasound doppler of the hepatic and splenic veins and inferior vena cava in assessment B   C 
   of portal venous hypertension or thrombosis (41210)  
   CT of the abdomen triphasic study – liver (41300) B   D 
   MR study of the liver/pancreas (41400) B   E 
   MR study of the liver/pancreas pre and post contrast (41410) B   E 
   MRCP (41420) B   D 
   MR study of the abdomen with MRCP (41430) B   E 
   MR study of the abdomen pre and post contrast with MRCP (41440) B   E 
              Renal tract 
  X-ray tomography of the renal tract (42100)   B 
   X-ray excretory urogram including tomography (42110)    B 
   X-ray excretory urogram including tomography with micturating study (42115)    B 
   X-ray cystography (42120)    B 
   X-ray urethrography (42130)    B 
   X-ray micturating cysto-urethrography (42140)    B 
   X-ray retrograde/prograde pyelography (42150) A   B 
   X-ray prograde pyelogram – percutaneous (42160) A   D 
   Ultrasound study of the renal tract including bladder (42200)    B 
   Ultrasound doppler for resistive index in vessels of transplanted kidney (42205)    B 
   Ultrasound study of the renal arteries including Doppler (42210)    C 
   CT of the renal tract for a stone (42300) B   D 
   MR of the renal tract for obstruction (42400) B   D 
   MR of the kidneys without contrast (42410) B   E 
   MR of the kidneys pre and post contrast (42420) B   E 
               Reproductive system 
   X-ray pelvimetry single (43100)    B 
   X-ray pelvimetry multiple views (43110)    B 
   X-ray hystero-salpingography (43120) A   A 
   X-ray hystero-salpingography with introduction of contrast (43130) A   C 
   Ultrasound study of the pelvis transabdominal (43200)    B 
   Ultrasound study of the female pelvis transvaginal (43205)    B 
   Ultrasound study of the prostate transrectal (43210) B   B 
   Ultrasound transrectal prostate volume for brachytherapy (43215) B   B 
   Ultrasound study of the testes (43220)    B 
   Ultrasound study for male impotence including doppler and injection of vaso contrictor (43225) A   C 
   Ultrasound guided transvaginal aspiration for ova (43230) B   B 
   Ultrasound guided amniocenthesis (43240) B   B 
   Ultrasound study of the pregnant uterus, first trimester (43250)    B 
   Ultrasound study of the pregnant uterus, second trimester (43260)    B 
   Ultrasound study of the pregnant uterus, third trimester, first visit (43270)    B 
   Ultrasound study of the pregnant uterus, third trimester, follow-up visit (43273)    B  
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     Ultrasound doppler of the umbilical cord for resistive index (43280)   B 
     CT pelvimetry – Topogram (43300)   B 
    MR study of pelvic reproductive organs - limited study (43400) B   D 
    MR study for pelvimetry 
(43405) B   D   
  MR study of pelvic reproductive organs - complete – uncontrasted (43410) B   C 
       MR study of pelvic reproductive organs - complete – pre and post contrast (43420) B   E 
  
 Aorta and vessels   
     Ultrasound study of abdominal aorta and branches including Doppler (44200)   C 
   Ultrasound study of the IVC and pelvic veins including Doppler (44205)    C 
   CT angiography of abdominal aorta and branches (44300) B   E 
   CT angiography of the abdominal aorta and branches and pre and post contrast study of the upper abdomen (44305) B  E 
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   CT angiography of the pelvis (44310) B   E 
   CT angiography of the abdominal aorta and pelvis (44320) B   E 
   CT angiography of the abdominal aorta and pelvis and pre and post contrast study of the upper abdomen and pelvis (44325) B   E 
   CT portogram (44330) B  E 
   MR angiography of abdominal aorta and branches (44400) B   E   
   Arteriography of abdominal aorta alone (44500) B   D 
   Arteriography of aorta plus coeliac, mesenteric branches (44503) B   E 
   Arteriography of aorta plus renal, adrenal branches (44505) B   E 
   Arteriography of aorta plus renal, non-visceral branches (44507) B   E 
   Arteriography of coeliac, mesenteric vessels alone (44510) B   E 
      Arteriography of renal, adrenal vessels alone (44515) B   D 
   Arteriography of non-visceral abdominal vessels alone (44517) B   E 
   Arteriography of internal and external iliac vessels alone (44520) B   E 
   Venography of internal and external iliac veins alone (44525) B   E 
   Corpora cavernosography (44530) B   D 
   Vasography, vesciculography (44535) B   D 
   Venography of inferior vena cava (44540) B   D 
   Venography of hepatic veins alone (44543) B   E 
   Venography of inferior vena cava and hepatic veins (44545) B   E 
   Venography of lumbar azygos system alone (44550) B   D 
   Venography of inferior vena cava and lumbar azygos veins (44555) B   E 
   Venography of renal, adrenal veins alone (44560) B   D 
   Venography of inferior vena cava and renal/adrenal veins (44565) B   E 
   Venography of spermatic, ovarian veins alone (44570) B   D 
   Venography of inferior vena cava, renal, spermatic, ovarian veins (44573) B   E 
   Venography indirect splenoportogram (44580) B   D 
   Venography direct splenoportogram (44583) B   D 
   Venography transhepatic portogram (44587) B   D  
           
               Spine, Pelvis and Hips 
               General 
   X-ray of the spine scoliosis view AP only (50100)    B 
   X-ray of the spine scoliosis view AP and lateral (50105)    C  
   X-ray of the spine scoliosis view AP and lateral including stress views (50110)    C 
   X-ray bone densitometry (50120)    C 
   X-ray guided lumbar puncture (50130) A   B 
   X-ray guided cisternal puncture cisternogram (50140) A   D 
   CT quantitive bone mineral density (50300) B   B 
   Arteriogram of the spinal column and cord, all vessels (50500) B   E 
   Venography of the spinal, paraspinal veins (50510) A   E  
               Cervical 
   X-ray f the cervical spine, stress views only (51100)    A 
   X-ray of the cervical spine, one or two views (51110)    A 
   X-ray of the cervical spine, more than two views (51120)    B 
   X-ray of the cervical spine, more than two views including stress views (51130)    B 
   X-ray Tomography cervical spine (51140)    B 
   X-ray myelography of the cervical spine (51160) B   B 
   X-ray discography cervical spine per level (51170) A   B 
   CT of the cervical spine limited study (51300) B   C 
   CT of the cervical spine – regional study (51310) B   C 
   CT of the cervical spine – complete study (51320) B   D 
   CT of the cervical spine pre and post contrast (51330) B   D 
   CT myelography of the cervical spine (51340) B   D 
   CT myelography of the cervical spine following myelogram (51350) B   D 
   MR of the cervical spine, limited study (51400) B   D 
   MR of the cervical spine and cranio-cervical junction (51410) B   E 
   MR of the cervical spine and cranio-cervical junction pre and post contrast (51420) B   E 
 Thoracic 
   X-ray of the thoracic spine, one or two views (52100)    A 
    X-ray of the thoracic spine, more than two views (52110)    B 
    X-ray tomography thoracic spine (52120)    B 
   X-ray of the thoracic spine, more that two views including stress views (52140)    B 
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   CT of the thoracic spine limited study (52300) B   C 
   CT of the thoracic spine – regional study (52305) B    C 
   CT of the thoracic spine complete study (52310) B   D 
   CT of the thoracic spine pre and post contrast (52320) B   E 
   CT myelography of the thoracic spine (52330) B   D 
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   CT myelography of the thoracic spine following myelogram (52340) B  D 
   MR of the thoracic spine, limited study (52400) B    D 
   MR of the thoracic spine (52410) B   E 
   MR of the thoracic spine pre and post contrast (52420) B    E  
 Lumbar 
   X-ray of the lumbar spine – stress study only (53100)     A 
   X-ray of the lumbar spine, one or two views (53110)     A 
   X-ray of the lumbar spine, more than two views (53120)     B 
   X-ray of the lumbar spine, more that two views including stress views (53130)    B 
   X-ray tomography lumbar spine (53140)    B 
   X-ray myelography of the lumbar spine (53160) B   B 
   X-ray discography lumbar spine per level (53170) B   B 
   CT of the lumbar spine limited study (53300) B   C 
   CT of the lumbar spine – regional study (53310) B   C 
   Ct of the lumbar spine complete study (53320) B   D 
   CT of the lumbar spine pre and post contrast (53330) B   D 
   CT myelography of the lumbar spine (53340) B   D 
   CT myelography of the lumbar spine following myelogram (53350) B   D 
   MR of the lumbar spine, limited study (53400) B    D 
   MR of the lumbar spine (53410) B   E 
   MR of the lumbar spine pre and post contrast (53420) B   E 
  
             Sacrum 
   X-ray of the sacrum and coccyx (54100)     A 
   X-ray of the sacro-iliac joints (54110)    B 
   X-ray tomography – sacrum and/or coccyx (54120)    B  
   CT of the sacrum – limited study (54300) B   B 
   CT of the sacrum – complete study – uncontrasted (54310) B    D 
   CT of the sacrum with contrast (54320) B   D 
   CT of the sacrum pre and post contrast (54330) B   D 
   MR of the sacrum (54400) B   E 
  MR of the sacrum pre and post contrast (54410) B  E 
             Pelvis  
   X-ray of the pelvis (55100)    A 
   X-ray tomography – pelvis (55110)     B 
   CT of the bony pelvis limited (55300) B    C 
   CT of the bony pelvis complete uncontrasted (55310) B    D 
   CT of the bony pelvis complete 3D recon (55320) B   D 
   CT of the bony pelvis with contrast (55330) B    D 
   CT of the bony pelvis – pre and post contrast (55340) B    D 
   MR of the bony pelvis (55400) B   E 
   MR of the bony pelvis pre and post contrast (55410) B   E 
  Hips 
   X-ray of the left hip (56100)     A 
   X-ray of the right hip (56110)     A 
   X-ray pelvis and hips (56120)    B 
   X-ray tomography – hip (56130)     B 
   X-ray of the hip/s – stress study (56140)     B 
   X-ray arthrography of the hip joint including introduction contrast (56150)     C 
   X-ray guidance and introduction of contrast into hip joint only (56160)    B 
   Ultrasound of the hip joints (56200)    B 
   CT of hip – limited (56300) B   C 
   CT of hip – complete (56310) B   D 
   CT of hip – complete with 3D recon (56320) B   D 
   CT of hip with contrast (56330) B   D 
   CT of hip pre and post contrast (56340) B   D 
   MR of the hip joint/s, limited study (56400) B   D 
   MR of the hip joint/s (56410) B   E 
   MR of the hip joint/s, pre and post contrast (56420) B   E 
 
 Upper limbs 
                General 
   X-ray upper limbs - any region - stress studies only (60100)    A 
   X-ray upper limbs - any region – tomography (60110)    B 
   Ultrasound upper limb – soft tissue - any region (60200)    B 
   Ultrasound of the peripheral arterial system of the left arm including B mode,  
   pulse and colour Doppler (60210)     B 
   Ultrasound of the peripheral arterial system of the right arm including B mode, 
   pulse and colour Doppler (60220)    B 
   Ultrasound peripheral venous system upper limbs including pulse and colour Doppler 
   for deep vein thrombosis(60230)    B 
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   CT of the upper limbs limited study (60300) B   C 
   CT angiography of the upper limb (60310) B   E 
   MR of the upper limbs limited study, any region (60400) B   D 
   MR angiography of the upper limb (60410) B   E 
   Arteriogram of subclavian, upper limb arteries alone, unilateral (60500) B   D 
   Arteriogram of subclavian, upper limb arteries alone, bilateral (60510) B   E 
   Arteriogram of aortic arch, subclavian, upper limb, unilateral (60520) B   D 
   Arteriogram of aortic arch, subclavian, upper limb, bilateral (60530) B   E 
   Venography, antegrade of upper limb veins, unilateral (60540) B   B 
   Venography, antegrade of upper limb veins, bilateral (60550) B   D 
   Venography, retrograde of upper limb veins, unilateral (60560) B   B 
   Venography, retrograde of upper limb veins, bilateral (60570) B   E 
   Venography, shuntogram, dialysis access shunt (60580) B   D  
                Shoulder 
   X-ray of the left clavicle (61100)    A 
   X-ray of the right clavicle (61105)    A 
   X-ray of the left scapula (61110)    A 
   X-ray of the right scapula (61115)    A 
   X-ray of the left acromio-clavicular joint (61120)    A 
   X-ray of the right acromio-clavicular joint (61125)    A 
   X-ray of acromio-clavicular joints plus stress studies bilateral (61128)    B 
   X-ray of the left shoulder (61230))    A 
   X-ray of the right shoulder (61135)    A 
   X-ray of the left shoulder plus subacromial impingement views (61140)    B 
   X-ray of the right shoulder plus subacromial impingement views (61145)    B 
   X-ray of the left subacromial impingement views only (61150)    B 
   X-ray of the right subacromial impingement views only (61155)    B 
   X-ray arthrography shoulder joint including introduction of contrast (61160)    C 
   X-ray guidance and introduction of contrast into shoulder joint only (61170)    B 
   Ultrasound of the left shoulder joint (61200)    B 
   Ultrasound of the right shoulder joint (61210)    B 
   CT of the left shoulder joint – uncontrasted (61300) B   D 
   CT of the right shoulder joint – uncontrasted (61305) B   D 
   CT of the left shoulder – complete with 3D recon (61310) B   D  
   CT of the right shoulder – complete with 3D recon (61315) B   D 
   CT of the left shoulder joint - pre and post contrast (61320) B  D 
   CT of the right shoulder joint - pre and post contrast (61325) B  D 
  
   MR of the left shoulder (61400) B  E 
   MR of the right shoulder (61405) B       E 
   MR of the left shoulder pre and post contrast (61410) B     E  
   MR of the right shoulder pre and post contrast (61415) B   E 
            Humerus 
   X-ray of the left humerus (62100)    A  
   X-ray of the right humerus (62105)    A  
   CT of the left upper arm (62300) B  D 
   CT of the right upper arm (62305) B  D       
  
   CT of the left upper arm contrasted (62310) B  D 
   CT of the right upper arm contrasted (62315) B  D 
   CT of the left upper arm pre and post contrast (62320) B  D  
   CT of the right upper arm pre and post contrast (62325) B  D  
   MR of the left upper arm (62400) B  E 
   MR of the right upper arm (62405) B  E  
   MR of the left upper arm pre and post contrast (62410) B  E 
   MR of the right upper arm pre and post contrast (62415) B  E 
 Elbow 
    X-ray of the left elbow (63100)   A             
   X-ray of the right elbow (63105)   A  
   X-ray of the left elbow with stress (63110)   B 
   X-ray of the right elbow with stress (63115)   B 
   X-ray arthrography elbow joint including introduction of contrast (63120)   C      
   X-ray guidance and introduction  of contrast into elbow joint only (63130)   B 
   Ultrasound of the left elbow joint (63200)   B  
   Ultrasound of the right elbow joint (63205)   B 
   CT of the left elbow (63300) B  D 
   CT of the right elbow (63305) B  D 
   CT of the left elbow – complete with 3D recon (63310) B  D  
   CT of the right elbow – complete with 3D recon (63315) B  D 
  
   CT of the left elbow contrasted (63320) B  D   
   CT of the right elbow contrasted (63325) B  D  
   CT of the left elbow pre and post contrast (63330) B  D 
  
   CT of the right elbow pre and post contrast (63335) B  D  
   MR of the left elbow (63400) B  E              
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   MR of the right elbow (63405) B  E 
   MR of the left elbow pre and post contrast (63410) B  E 
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              Forearm 
   X-ray of the left forearm (64100)   A             
  
   X-ray of the right forearm (64105)   A 
   X-ray peripheral bone densitometry (64110)   A  
   CT of the left forearm (64300) B  D 
   CT of the right forearm (64305) B  D 
   CT of the left forearm contrasted (64310) B  D  
   CT of the right forearm contrasted (64315) B  D 
   CT of the left forearm pre and post contrast (64320) B  D  
   CT of the right forearm pre and post contrast (64325) B  D 
  
   MR of the left forearm (64400) B  E 
  
   MR of the right forearm (64405) B  E 
   MR of the left forearm pre and post contrast (64410) B  E 
   MR of the right forearm pre and post contrast (64415) B  E 
              Hand and Wrist 
    X-ray of the left hand (65100)   A 
   X-ray of the right hand (65105)   A 
   X-ray of the left hand – bone age (65110)   A 
   X-ray of a finger (65120)   A 
   X-ray of the left wrist (65130)   A 
   X-ray of the right wrist (65135)   A 
   X-ray of the left scaphoid (65140)   A 
   X-ray of the right scaphoid (65145)   A 
  
   X-ray of the left wrist, scaphoid and stress views (65150)   B 
   X-ray of the right wrist, scaphoid and stress views (65155)   B  
   X-ray arthrography wrist joint including introduction of contrast (65160)   C 
   X-ray guidance and introduction of contrast into wrist joint only (65170)   B 
   Ultrasound of the left wrist (65200)   B 
   Ultrasound of the right wrist (65210)   B 
   CT of the left wrist and hand (65300) B  D 
   CT of the right wrist and hand (65305) B  D 
   CT of the left wrist and hand - complete with 3D recon (65310) B  D 
   CT of the right wrist and hand - complete with 3D recon (65315) B  D 
   CT of the left wrist and hand contrasted (65320) B  D 
   CT of the right wrist and hand contrasted (65325) B  D 
   CT of the left wrist and hand pre and post contrast (65330) B  D 
   CT of the right wrist and hand pre and post contrast (65335) B  D 
   MR of the left wrist and hand (65400) B  E 
  
   MR of the right wrist and hand (65405) B  E 
   MR of the left wrist and hand pre and post contrast (65410) B  E 
   MR of the right wrist and hand pre and post contrast (65415) B  E 
 
             Lower Limbs 
              General 
    X-ray lower limbs - any region- stress studies only (70100)   B 
   X-ray lower limbs - any region-tomography (70110)   B 
   X-ray of the lower limbs full length study (70120)   B 
   Ultrasound lower limb – soft tissue - any region (70200)   B 
   Ultrasound of the peripheral arterial system of the left leg including B mode, pulse and     
   colour Doppler (70210)   B 
   Ultrasound of the peripheral arterial system of the right leg including B mode, pulse and  
   colour Doppler (70220)   B 
   Ultrasound peripheral venous system lower limbs including pulse and colour doppler for  
   deep vein thrombosis (70230)   C 
   Ultrasound peripheral venous system lower limbs including pulse and colour doppler in erect and  
   supine position including all compression and reflux manoeuvres, deep and superficial  
   systems bilaterally (70240)   C  
   CT of the lower limbs limited study (70300) B  C 
   CT angiography of the lower limb (70310) B  E 
   CT angiography abdominal aorta and outflow lower limbs (70320) B  E 
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   MR of the lower limbs limited study (70400) B  D 
   MR angiography of the lower limb (70410) B  E  
   MR angiography of the abdominal aorta and lower limbs (70420) B  E 
   Angiography of pelvic and lower limb arteries unilateral (70500) B  D  
   Angiography of pelvic and lower limb arteries bilateral (70505) B  E 
   Angiography of abdominal aorta, pelvic and lower limb vessels unilateral (70510) B  D 
   Angiography of abdominal aorta, pelvic and lower limb vessels bilateral (70515) B  E 
   Angiography translumbar aorta with full peripheral study (70520) B  D 
   Venography, antegrade of lower limb veins, unilateral (70530) B  B 
   Venography, antegrade of lower limb veins, bilateral (70535) B  D 
   Venography, retrograde of lower limb veins, unilateral (70540) B  B 
   Venography, retrograde of lower limb veins, bilateral (70545) B  E 
   Lymphangiography, lower limb, unilateral (70560) B  D 
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 Femur 
    X-ray of the left femur (71100)    A  
   X-ray of the right femur (71105)   A 
   CT of the left femur (71300) B  D  
   CT of the right femur (71305) B  D 
   CT of the left upper leg contrasted (71310) B  D 
   CT of the right upper leg contrasted (71315) B  D 
   CT of the left upper leg pre and post contrast (71320) B  D 
   CT of the right upper leg pre and post contrast (71325) B  D 
   MR of the left upper leg (71400) B  E 
   MR of the right upper leg (71405) B  E 
   MR of the left upper leg pre and post contrast (71410) B  E 
   MR of the right upper leg pre and post contrast (71415) B  E 
            Knee 
    X-ray of the left knee one or two views (72100)   A  
   X-ray of the right knee one or two views (72105)   A 
   X-ray of the left knee, more than two views (72110)   A 
   X-ray of the right knee, more than two views (72115)   A 
   X-ray of the left knee including patella (72120)   B 
   X-ray of the right knee including patella (72125)   B 
   X-ray of the left knee with stress views (72130)   B 
   X-ray of the right knee with stress views (72135)   B 
  
   X-ray of left patella (72140)   A  
   X-ray of right patella (72145)   A  
   X-ray both knees standing – single view (72150)   A 
   X-ray arthrography knee joint including introduction of contrast (72160)   C 
   X-ray guidance and introduction of contrast into knee joint only (72170)   B 
   Ultrasound of the left knee joint (72200)   B  
   Ultrasound of the right knee joint (72205)   B 
   CT of the left knee (72300) B  D 
   CT of the right knee (72305) B  D 
   CT of the left knee complete study with 3D reconstructions (72310) B  D 
   CT of the right knee complete study with 3D reconstructions (72315) B  D 
   CT of the left knee contrasted (72320) B  D 
   CT of the right knee contrasted (72325) B  D 
   CT of the left knee pre and post contrast (72330) B  D 
   CT of the right knee pre and post contrast (72335) B  D 
   MR of the left knee (72400) B  E 
   MR of the right knee (72405) B  E  
   MR of the left knee pre and post contrast (72410) B  E 
   MR of the right knee pre and post contrast (72415) B  E 
  Lower Leg 
    X-ray of the left lower leg (73100)   A 
     X-ray of the right lower 
leg (73105)   A  
   CT of the left lower leg (73300) B  D 
   CT of the right lower leg (73305) B  D 
   CT of the left lower leg contrasted (73310) B  D 
   CT of the right lower leg contrasted (73315) B  D  
   CT of the left lower leg pre and post contrast (73320) B  D 
   CT of the right lower leg pre and post contrast (73325) B  D 
   MR of the left lower leg (73400) B  E 
   MR of the right lower leg (73405) B  E 
   MR of the left lower leg pre and post contrast (73410) B  E 
   MR of the right lower leg pre and post contrast (73415) B  E 
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            Ankle and Foot 
    X-ray of the left ankle (74100)   A 
    X-ray of the right ankle (74105)   A 
   X-ray of the left ankle with stress views (74110)   B 
   X-ray of the right ankle with stress views (74115)   B 
   X-ray of the left foot (74120)   A 
   X-ray of the right foot (74125)   A 
   X-ray of the left calcaneus (74130)   A 
   X-ray of the right calcaneus (74135)   A 
   X-ray of both feet – standing – single view (74140)   A 
   X-ray of a toe (74145)   A 
   X-ray of the sesamoid bones one or both sides (74150)   A 
   X-ray arthrography ankle joint including introduction of contrast (74160)   C 
   X-ray guidance and introduction of contrast into ankle joint (74170)   B 
   Ultrasound of the left ankle (74210)   B 
   Ultrasound of the right ankle (74215)   B 
   Ultrasound of the left foot (74220)   B 
   Ultrasound of the right foot (74225)   B 
   Ultrasound bone densitometry (74290)   A 
   CT of the left ankle/foot (74300) B  D 
   CT of the right ankle/foot (74305) B  D 
   CT of the left ankle/foot – complete with 3D recon (74310) B  D 
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   CT of the left ankle/foot contrasted (74320) B  D 
   CT of the right ankle/foot contrasted (74325) B  D 
   CT of the left ankle/foot pre and post contrast (74330) B  D 
   CT of the right ankle/foot pre and post contrast (74335) B  D 
   MR of the left ankle (74400) B  E 
   MR of the right ankle (74405) B  E 
   MR of the left ankle pre and post contrast (74410) B  E 
   MR of the right ankle pre and post contrast (74415) B  E 
   MR of the left foot (74420) B  E 
   MR of the right foot (74425) B  E 
   MR of the left foot pre and post contrast (74430) B  E 
   MR of the right foot pre and post contrast (74435) B  E 
   
 Intervention 
             General 
   Percutaneous abscess, cyst drainage, any region (80600)   C 
   Fine needle aspiration biopsy, any region (80605) A  B 
   Cutting needle, trochar biopsy, any region (80610) A A B 
   Tumour/cyst ablation chemical (80620)   D 
  Tumour ablation radio frequency, per lesion (80630)   D 
   Insertion of CVP line in radiology suite (80640) C  C 
   Peripheral central venous line insertion (80645)   C 
   Infiltration of a peripheral joint, any region (80650)   B 
 Neuro intervention 
    Intracranial aneurysm occlusion, direct (81600) C  E 
     Intracranial 
arteriovenous shunt occlusion (81605) C  E  
   Dural sinus arteriovenous shunt occlusion (81610) C  E 
   Extracranial arteriovenous shunt occlusion (81615) C  E 
   Extracranial arterial embolisation (head and neck) (81620) C  E 
   Caroticocavernous fistula occlusion (81625) C  E 
   Intracranial angioplasty for stenosis, vasospasm (81630) C D E 
   Intracranial stent placement (including PTA )(81632) C D E 
   Temporary balloon occlusion test (81635) C  E 
   Permanent carotid or vertebral artery occlusion (including occlusion  test) (81640) B  E 
   Intracranial aneurysm occlusion with balloon remodeling (81645) B B E 
   Intracranial aneurysm occlusion with stent assistance (81650) B B E 
   Intracranial thrombolysis, catheter directed (81655) B B E 
   Nerve block, head and neck, per level (81660) B  B 
   Neurolysis, head and neck, per level (81665) B  D 
   Nerve block, head and neck, radio frequency, per level (81670) B  C 
   Nerve block, coeliac plexus or other regions, per level (81680) B  C    
  
 Thorax 
   Chest drain insertion (82600) A  B 
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   Trachial, bronchial stent insertion (82605) B B D 
             Gastrointestinal 
   Oesophageal stent insertion (83600) C  C 
   GIT balloon dilation (83605) B B D 
   GIT stent insertion (non-oesophageal) (83610) C  D 
   Percutaneous gastrostomy, jejunostomy (83615) A B D 
            Hepatobiliary 
   Percutaneous biliary drainage, external (84600) B  D 
   Percutaneous external/internal biliary drainage(84605) B  D 
   Permanent biliary stent insertion (84610) B C D 
   Drainage tube replacement (84615)    D 
   Percutaneous bile duct stone or foreign object removal (84620) C  D 
   Percutaneous gall bladder drainage (84625) B  D 
   Percutaneous gallstone removal, including drainage (84630) B B E 
   Transjugular liver biopsy (84635) B B D 
   Transjugular intrahepatic Portosystemic shunt (84640) C  E 
   Transhepatic Portogram including venous sampling, pressure studies (84645) C  E 
   Transhepatic Portogram with embolisation of varices (84650) C  E 
   Percutaneous hepatic tumour ablation (84655)    C 
   Percutaneous hepatic abscess, cyst drainage (84660) A A C 
   Hepatic chemoembolization (84665)    E 
   Hepatic arterial infusion catheter placement (84670) B C D 
              Urogenital 
    Percutaneous nephrostomy, external drainage (85600) B B D 
   Percutaneous double J stent insertion including access (85605) B B D 
   Percutaneous renal stone, foreign body removal including access (85610) C  D 
   Percutaneous nephrostomy tract establishment (85615) B B D 
   Change of nephrostomy tube (85620)    C 
   Percutaneous cystostomy (85625)  A  C 
   Urethral balloon dilatation (85630)  A A B 
   Urethral stent insertion (85635)  A  D 
   Renal cyst ablation (85640)    B 
   Renal abscess, cyst drainage (85645) B  C 
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              Spinal 
    Spinal vascular malformation embolization (86600)  C  E 
   Vertebroplasty per level (86605) C B D 
   Facet joint block per level, uni- or bilateral (86610)    C 
   Spinal nerve block per level, uni- or bilateral (86615)    C 
   Epidural block (86620)    C 
   Chemonucleolysis, including discogram (86625)    C 
   Spinal nerve ablation per level (86630)    C 
              Vascular 
    Percutaneous transluminal angioplasty: aorta, IVC (87600)  C  D  
   Percutaneous transluminal angioplasty: iliac (87601)  C  D  
   Percutaneous transluminal angioplasty: femoropopliteal (87602) C B D 
   Percutaneous transluminal angioplasty: subpopliteal (87603) C  D 
   Percutaneous transluminal angioplasty: brachiocephalic (87604) C  D  
   Percutaneous transluminal angioplasty: subclavian, axillary (87605) C  D 
   Percutaneous transluminal angioplasty: extracranial carotid (87606)  C  E 
   Percutaneous transluminal angioplasty: extracranial vertebral (87607) C  E 
   Percutaneous transluminal angioplasty: renal (87608) C  D 
   Percutaneous transluminal angioplasty: coeliac, mesenteric (87609) C B E 
   Aorta stent-graft placement (87620) C C E 
   Stent insertion (including PTA): aorta, IVC (87621) C  D 
   Stent insertion (including PTA): iliac (87622)  C C D 
   Stent insertion (including PTA): femoropopliteal (87623) C  D 
   Stent insertion (including PTA): subpopliteal (87624) C  D 
   Stent insertion (including PTA): brachiocephalic (87625) C  D 
   Stent insertion (including PTA): subclavian, axillary (87626) C  E 
   Stent insertion (including PTA): extracranial carotid (87627) C  E 
   Stent insertion (including PTA): extracranial vertebral (87628) C  D 
   Stent insertion (including PTA): renal (87629) C  E 
   Stent insertion (including PTA): coeliac, mesenteric (87630) C  E 
   Stent-graft placement: iliac (87631)  C C E 
   Stent-graft placement: femoropopliteal (87632)  C C E 
   Stent-graft placement: brachiocephalic (87633)  C C E 
   Stent-graft placement: subclavian, axillary (87634)  C C E 
   Stent-graft placement: extracranial carotid (87635) C C E 
   Stent-graft placement: extracranial vertebral (87636) C C E 
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   Stent-graft placement: renal (87637) C C E 
   Stent-graft placement: coeliac, mesenteric (87638) C C E 
   Thrombolysis in angiography suite, per 24 hours (87650)    D 
   Aspiration, rheolytic thrombectomy (87651)    E 
   Atherectomy, per vessel (87652) B D E 
   Percutaneous tunnelled / subcutaneous arterial or venous central or other line insertion (87653) C  D 
   Percutaneous sclerotherapy, vascular malformation (87655) B B D 
   Embolisation, mesenteric (87660) B C E 
   Embolisation, renal (87661) B C E 
   Embolisation, bronchial, intercostals (87662) B C E 
   Embolisation, pulmonary arteriovenous shunt (87663) B C E 
   Embolisation, abdominal, other vessels (87664) B C E 
   Embolisation, thoracic, other vessels (87665)  B C E 
   Embolisation, upper limb (87666)  B C E 
   Embolisation, lower limb (87667)  B C E 
   Embolisation, pelvis, non-uterine (87668)  B C E 
   Embolisation, uterus (87669)  B C E 
   Embolisation, spermatic, ovaria veins (87670) B C E 
   Inferior vena cava filter placement (87680) B C D 
   Intravascular foreign body removal (87681)  C D D 
   Revision of access port (tunnelled or implantable) (87682) A B C 
   Removal of access port (tunnelled or implantable) (87683)  A B C 
   Superior petrosal venous sampling (87690)    E 
   Pancreatic stimulation test (87691)    E 
   Transportal venous sampling (87692)    E 
   Adrenal venous sampling (87693)    E 
   Parathyroid venous sampling (87694)    E 
   Renal venous sampling (87695)    E 
              Lithotripsy 
     Lithotripsy is a non-invasive procedure used to break up stones inside the patient’s body.  
             1st Electro Shock wave Lithotripsy (56245)    E 
          2nd Electro Shock wave Lithotripsy (56246)    E 
         1st Laser Lithotripsy (56222)    E 
             2nd Laser Lithotripsy (56223)    E 
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